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Abstract 
Drug delivery systems for time release of recombinant human bone morphogenetic 
protein-2 (rhBMP-2) and antibiotics in orthopedic surgeries continue to be developed. Recently, 
a biodegradable novel polymeric matrix has been developed for this purpose. We hypothesized 
that impregnation of the matrix with rhBMP-2 would enhance bone healing. The objectives of 
the study were to characterize elution of rhBMP-2 and two antimicrobials (tigecycline, 
tobramycin) from the matrix, and bone response to the matrix in the presence or absence of 
rhBMP-2 and antimicrobials. 
In vitro elution of tigecycline, tobramycin, and rhBMP-2 from the matrix was 
investigated. Drug concentration in media were measured on days 1-6, 8, 10, 13, 15, 17, 21, 25, 
28, and 30 using high pressure liquid chromatography/mass spectrometry/mass spectrometry 
(HPLC/MS/MS; antimicrobials) and ELISA (rhBMP-2). In vivo testing was done using a unicortical 
defect created into each tibia of twenty adult goats. Animals were randomly assigned to one of 
5 groups: 1) control (untreated defect); 2) matrix; 3) matrix+ antimicrobials 
(tigecycline+tobramycin); 4) matrix+rhBMP-2; and 5) matrix+antimicrobials+rhBMP-2. Plasma 
concentration of tigecycline and tobramycin and serum concentration of rhBMP-2 were 
measured by the above techniques on days 1-7, 9, 11, 13, 15, 17, 22, 26, and 30. Bone response 
was assessed on days 0, 14, and 30 using radiographic scoring and dual energy X-ray 
absorptiometry (bone mineral density [BMD]). After euthanasia on day 30, histomorphologic 
analyses of the bone defects were done. Categorical variables were analyzed using a 
generalized linear model, and continuous variables using an ANOVA with P < 0.05 considered 
significant. 
In vitro elution was characterized by a rapid release on day 1 followed by a slow release 
until day 30 for both antimicrobials and rhBMP-2. Plasma antimicrobial concentrations showed 
continued release throughout the study period. Serum rhBMP-2 concentration, radiographic 
scores and BMD were not significantly different between groups. Periosteal and endosteal 
reaction surface areas were significantly greater surrounding the defects in group 4 
  
(matrix+rhBMP-2). There was no significant difference between the groups for the percent of 
bone filling the defect.  
The matrix served as an appropriate antimicrobial and rhBMP-2 delivery system and 
successfully stimulated bone production when rhBMP-2 was present. 
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Chapter 1 - Introduction 
Morbidity associated with open comminuted fractures and secondary osteomyelitis is 
well recognized. Operative treatments (excision of infected and devascularized tissues, 
obliteration of dead space, restoration of blood supply and soft-tissue coverage, stabilization 
and reconstruction of the damaged bone)1, removal of all foreign bodies and systemic 
antimicrobial therapy are three crucial components of the treatment of these cases. A long-
term course of systemic antibiotherapy has been considered essential, but these prolonged 
therapies can result in side effects or toxicity. In order to achieve therapeutic drug 
concentration in the affected bone, high systemic doses are generally required which can 
further worsen toxic side effects. Despite intensive therapy, advances in surgical techniques, 
and development of new antimicrobials, relapse rates are still significant and treatment of 
chronic osteomyelitis remains challenging 2.  
A possible adjunct therapy for osteomyelitis is the local delivery of antimicrobial drugs 
into the site of infection. This approach offers the promises of minimum side effects and 
maximal bactericidal concentration and effectiveness3. In fact, application of local 
antimicrobials for the treatment of open fractures has been shown to significantly decrease the 
rate of acute and chronic osteomyelitis in humans4-6 and in animal models7,8. Most carriers used 
for the local delivery of antimicrobial agents into the bone may be classified into two 
categories: 1) non-biodegradable and 2) biodegradable9. The most commonly used non-
biodegradable carrier to locally deliver drugs to bone is polymethylmethacrylate (PMMA) bone 
cement used to construct antimicrobial impregnated beads2. For the last 20 to 30 years, 
antimicrobial impregnated PMMA implants have been employed in the treatment and 
prevention of osteomyelitis in humans9-13 and veterinary patients14-19. Antimicrobial 
impregnated in polymethylmethacrylate (PMMA) has offered local drug delivery with some 
success. However, the effect of the antimicrobial on the bone cement, the inconsistent elution 
of the antimicrobial, occasional foreign body reactions to the PMMA, possible development of a 
biofilm surrounding the cement, and the subsequent need to remove the PMMA beads at the 
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completion of antimicrobial release drives the need for superior antimicrobial delivery devices2. 
Implantable drug pumps have also been investigated20, 21 for the treatment of osteomyelitis. 
More recently, the use of various biodegradable systems for local delivery of antimicrobials has 
been investigated12,22. Biodegradable carriers include collagen sponge23-25, hydroxyapatite 
blocks, ceramics and cement26-32, plaster of Paris beads33-35, chitosan36-39, synthetic polymers 
(e.g. polylactide-polyglycolide (PLA/PGA), polyanhydride, polycaprolactone, dilactate, 
biomedical polyurethanes)22,38-41,41-57, fibrin clots58-63, bone xenograft64-66, demineralized bone 
matrix67, calcium sulfate3, β-tricalcium phosphate68-70, hyaluronic acid gel71, and monolein-
water gels72. Biodegradable inorganic and organic-inorganic composites have also been 
explored as antimicrobial delivery devices73. Surgical removal of biodegradable carriers 
becomes unnecessary when their rate of degradation is suitable to the period of release of the 
antimicrobial and tissue healing. In addition, secondary elution may occur later during the 
degradation phase of the scaffold, which could offer the benefit of increased antibacterial 
efficacy compared with that of non-biodegradable carriers. Biodegradable drug delivery 
vehicles may offer an opportunity to obliterate dead space and guide bone healing74-78.   
Regeneration of bone in traumatic or iatrogenic (orthopedic surgeries and primary 
tumor resection) critical sized defects, especially if infected, is of major concern to orthopedic 
surgeons. Large segmental osseous defects are challenging clinical problems. Ideally, secondary 
osteons progress from one fracture fragment to another when the fragments are in direct 
contact under compression. In critical sized defects (e.g. > 2-cm), bone replacement becomes 
necessary to stimulate osteogenesis2. Bone can be replaced by biologically similar substances 
and/or synthetic materials79. Cortical and/or cancellous bone autografting (also called 
autologous or autogenous bone grafts) is the current gold standard treatment of critical-sized 
bone defects in humans80 and veterinary patients80. Bone autografts first were reported to be 
used in animals by Merrem in 1810, and in human patients by Philipp von Walther in 182081,82. 
In current practice, similar bone autografts continue to be the gold standard for bone 
replacement because they contain the ideal combination of necessary components for bone 
regeneration: osteoprogenitor cells for osteogenesis, bone matrix for osteoconduction, bone 
morphogenetic proteins for osteoinduction. Disruption of blood supply to the autograft at the 
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time of harvest and the high rate of death of the osteoprogenitor cells of both cortical and 
cancellous bone grafts stimulated the development of vascularized bone grafts. Vascular 
autografts carried the most favorable biological potential to augment bone union. These 
pedicle autografts, or free flaps, have been successfully applied for the reconstruction of bone 
defects in humans83, but their use is limited. Despite incredible advances in surgical techniques, 
morbidity associated with graft harvest is well documented in the human literature84,85. Donor 
site morbidity is avoided when using bone allografts and xenografts, but these grafts lack 
osteoprogenitor cells, have a lower potency for osteoinduction and osteoconduction, and have 
an increased possibility of non-integration and rejection of the graft80.  
A wide variety of synthetic materials have been designed to replace or augment bone 
and include metals (e.g. stainless steel 316L, titanium), ceramics (e.g. aluminum oxide, synthetic 
hydroxyapatite, tricalcium phosphate, etc.), and plastics (e.g. PMMA cement, methacrylate 
cement, acrylic plastics, polymers such as polylactates and polyglycolates)86. Some of these 
bone substitutes are designed to enhance bone healing or regeneration and are biodegradable 
(e.g. hydroxyapatite, tricalcium phosphate, polylactates, polyglycolates). These materials can be 
used alone, or in combination, as carriers for antimicrobials to treat bone infection or provide 
growth promoting substances to enhance bone healing. Osteostimulatory factors may include 
bone morphogenetic proteins (BMPs), transforming growth factor-β (TGF- β), platelet-derived 
growth factors 1 and 2, osteogenic growth peptide, and others80. Bone morphogenetic proteins 
types 2, 4 and 7, and more recently BMP-6 and 9 have been reported to have excellent efficacy 
inducing bone formation86. The BMPs can be extracted from demineralized bone matrix87-90, 
but the most recent advance in the production of BMPs is the cloning of recombinant human 
morphgenetic bone proteins (rhBMPs)91. Tissue engineering studies have found that BMPs 
ideally should be released slowly and gradually, usually from a carrier, at a localized area over 
several weeks to allow optimized bone formation92. Two different BMPs are currently available 
in the United States for clinical use in humans. The Food and Drug Administration (FDA) has 
approved in 2002 a recombinant human form of BMP-2 (rhBMP-2) locally delivered by an 
absorbable purified collagen type I sponge as an autograft replacement for certain interbody 
spinal fusion proceduresa. Clinical approval was also granted for the use of this product in open 
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tibial fractures (2004), and certain oral and maxillofacial bone grafting procedures (sinus 
augmentations, localised alveolar ridge augmentations; 2007)86. Two  rhBMP-7 products are 
approved by the FDA under a Humanitarian Device Exemption and are indicated for use as an 
alternative to autografts in recalcitrant long bone nonunionsb  and lumbar spinal fusionc where 
use of autologous bone graft is unfeasible or is not expected to promote fusion and alternative 
treatments have failed. Both product use a purified Type I bovine collagen as the carrierb,c. 
Local delivery of BMPs also was reported to improve healing of open fractures in human 
patients93 and infected osseous sites in animal models94. These findings most likely are caused 
by the osteoinductive properties of BMPs, increasing the fracture stability and local vascular 
supply, and indirectly improving bone healing and local control of osteomyelitis95,96. The 
addition of osteoinductive agents such as rhBMP-2 to antimicrobials to be delivered locally 
could theoretically be synergistic and allow better and more rapid bone healing. 
More recently the use of composite materials that would mimic structures of bone have 
been investigated because they combine advantages and drawbacks from their components to 
try to develop the ideal bone drug delivery device for antimicrobials and/or BMPs. Ideally, these 
composite drug delivery devices should be capable of filling bone defects, providing a 
conductive scaffold for bone healing, and provide structural support to the injured bone. 
Orlumetd, in collaboration with the Nanotechnology Centere, has developed a novel 
polymeric bone matrix that is a biodegradable composite of demineralized bone matrix, 
polymer, and hydroxyapatite. All of these components are materials already in clinical use and 
approved by the FDA. This bone grafting scaffold has the potential to be used as a drug delivery 
system for controlled release of rhBMP-2, growth factors, antimicrobials, and other 
pharmaceuticals (e.g. antineoplastic agents). This drug-composite matrix possesses 
osteoconductive and osteoinductive properties with potential future applications in orthopedic 
and oromaxillary surgeries. This novel bone implant has undergone preliminary testing in oral 
surgery with success in human subjectsd. 
We hypothesized that temporal release of rhBMP-2 impregnated onto the Novel 
Polymeric Bone Matrix will enhance bone healing with or without temporal release of 
antimicrobials (tigecycline and tobramycin) also impregnated onto the matrix. 
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The objective of this study was to determine if the Novel Polymeric Bone Matrix acts as 
scaffold and appropriate carrier for antimicrobials and growth factors that would stimulate 
more rapid bone healing. These objectives were investigated using in vitro and in vivo models. 
The specific aims of the in vitro study were to determine the temporal release of rhBMP-2 and 
antimicrobials impregnated onto the matrix and to determine if the elution of these substances 
is affected by co-impregnation of antimicrobials and rhBMP-2. The specific aims of the in vivo 
study were to determine the response of cortical bone to the matrix alone and to the 
impregnation of antimicrobials or rhBMP-2 onto the matrix, as well as to determine if any 
interaction occurs with the co-impregnation of antimicrobials and rhBMP-2 onto the matrix. 
Further, the in vivo study was designed to determine systemic exposure of the goats to rhBMP-
2, tigecycline and tobramycin when locally delivered by the matrix. 
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Chapter 2 - Materials & Methods 
 IN VITRO EVALUATION OF rhBMP-2 AND ANTIMICROBIALS (TIGECYCLINE 
AND TOBRAMYCIN) ELUTION FROM THE NOVEL POLYMERIC BONE 
MATRIX 
 Preparation of the novel polymeric bone matrix 
The novel polymeric bone matrix (Figure B.1) was constituted of demineralized bone 
matrix, hydroxyapatite, and an absorbable polymer. The proprietary informationd,e of the exact 
constituents, their characteristics (molecular weight, porosity percent, source) and proportions 
were unknown by the author at the time of writing. For the in vivo experiment, the matrix was 
manufacturedd,e in a cylinder with a diameter of 3.5 mm and a length of 1.5 cm to facilitate its 
insertion into the unicortical bone defect model (in vivo experiment). The same configuration 
was used for the in vitro experiment. Based on the formula to compute the volume of a cylinder 
(Figure B.2), the matrix had a volume of 0.144 cm3. This volume was necessary for the 
calculation of the dosage of rhBMP-2 impregnated onto the matrix. 
 
 Impregnation of the novel polymeric bone matrix 
Reconstitution of the lyophilized rhBMP-2a (4.2 mg/vial) was done with sterile water to a 
final concentration of 0.75 mg/ml. The total volume of rhBMP-2 impregnated onto the matrix 
was 0.3 ml, which constituted a total dose of approximately 1.5 mg of rhBMP-2 per cm3 of 
matrix97. The lyophilized powder of tigecyclinef (50 mg/vial) was reconstituted using 0.9% 
sodium chloride solution for injection to a concentration of 50 mg/ml. A volume of 0.1 ml of the 
reconstituted tigecycline, which corresponds to an approximate dose of 5 mg of tigecycline was 
impregnated onto the matrix. A volume of 0.13 ml of a 40 mg/ml injectable solution of 
tobramycin sulfateg (contained within a multiple dose vial and stored at room temperature) 
was instilled on the matrix. This corresponded to an approximate dose of 5 mg of tobramycin 
sulfate. 
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Impregnation of all drugs was performed by slow instillation onto the matrix using a 
sterile tuberculin syringe and needle. All products were distributed uniformly across the entire 
matrix. 
 
 Evaluation of the rhBMP-2, tigecycline and tobramycin elution from the bone matrix 
Three novel polymeric bone matrixes were used for the in vitro experiment. One of 
them was impregnated with rhBMP-2 (1.5 mg per cm3 of matrix); the second was impregnated 
with tigecycline (5 mg) and tobramycin (5 mg); and the third was impregnated with rhBMP-2, 
tigecycline and tobramycin at the same doses. These impregnated bone matrixes were 
completely submerged in 10 ml of 0.9% sodium chloride solution (saline) in individual petri 
dishes with lid and incubated at 37oC (day 0). Supernatant was aspirated with a syringe and 
needle daily on days 1 through 6 and again on days 8, 10, 13, 15, 17, 21, 25, 28, and 30. After 
the supernatant had been obtained for analysis and on each day, the matrix and incubation 
well were rinsed three times with 10 ml of fresh saline. The matrix was then completely 
submerged in 10 ml of fresh saline before continuing incubation. A new syringe and needle 
were used between each steps (aspiration, rinse, and re-submersion). The supernatant was 
transferred to cryotubes and frozen at -80oC until rhBMP-2, tigecycline, and tobramycin assays 
were performed. 
 
 Determination of tigecycline concentration using LC/MS/MS 
Frozen supernatant samples were thawed at room temperature. A structurally related 
antibiotic, minocycline, was used as the internal standard.  The analyte (supernatant sample) 
and spiked internal standard were isolated from 200 µl of saline solution by protein 
precipitation using acetonitrile. Extracts were filtered using centrifugal filtersh and then 
evaporated to dryness at 50°C under nitrogen. The dried extracts were re-constituted in 200 µl 
of mobile phase A, vortexed and vialed for injection. Electrospray ionization and MS-MS 
analysis were carried out using a high-pressure liquid chromatography (HPLC) systemi coupled 
with a mass spectrometerj. Chromatographic separation of analyte and internal standard was 
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achieved using a C18 analytical columnk and a gradient elution from 100% mobile phase A (0.2% 
acetic acid in water) to 95% mobile phase B (0.2% acetic acid in acetonitrile) and re-
equilibration over a 5.0 minute runtime.  Identification and quantification were based on the 
following transitions:  
 Tigecycline     m/z586→m/z456 
 Minocycline        m/z458→m/z352 
The method was proven to be accurate and precise across a linear dynamic range of 1.0-
500 ng/ml. The level of quantification was therefore 1.0 ng/ml. 
 
 Determination of tobramycin concentration using LC/MS/MS 
A structurally related antibiotic, amikacin, was used as the internal standard.  The 
analyte and internal standard were isolated from 200 µl of saline solution by protein 
precipitation using trichloroacetic acid. Extracts were filtered using centrifugal filtersh and 
vialed for injection.  Electrospray ionization and MS-MS analysis were carried out using a HPLC 
systemi coupled with a mass spectrometerj. Chromatographic separation of analyte and internal 
standard was achieved using a C18 analytical columnk and a gradient elution from 100% mobile 
phase A (2mM ammonium acetate, 0.1% formic acid, 10mM heptafluorobutyric acid in water) 
to 90% mobile phase B (2mM ammonium acetate, 0.1% formic acid, 10mM heptafluorobutyric 
acid in acetonitrile) and re-equilibration over a 6.0 minute runtime.  Identification and 
quantification were based on the following transitions:  
 Tobramycin    m/z468→m/z163 
 Amikacin        m/z586→m/z163 
The method was proven to be accurate and precise across a linear dynamic range of 1.0-
500 ng/ml. The level of quantification was therefore 1.0 ng/ml. 
 
 Determination of rhBMP-2 concentration by sandwich ELISA 
Concentration of rhBMP-2 in the supernatant was measured with a commercial rhBMP-
2 enzyme-linked immunosorbent (ELISA) kitl. The kits were refrigerated at -4oC and all reagents 
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and samples (supernatant) were brought to room temperature before use. All samples and 
standards were assayed in duplicate and according to the manufacturer’s instructions. The 
reagents were prepared as follows. Twenty milliliters of wash buffer concentrate was added to 
distilled water to yield 500 ml of wash buffer. Twenty milliliters of calibrator diluent 
concentrate was diluted into distilled water to prepare 200 ml of calibrator diluent and was 
allowed to mix for at least 15 minutes before use. Color reagents A and B were mixed together 
in equal volumes within 15 minutes of use and protected from light after dissolution.  The BMP-
2 standard was diluted with 1 ml of distilled water to produce a stock solution of 20,000 pg/ml. 
The standard was gently agitated for at least 15 minutes before use to make dilutions. A serial 
dilution was performed from the stock solution to obtained 4000, 2000, 1000, 500, 250, 125, 
and 62.5 pg/ml of BMP-2. The 4000 pg/mL standard represented the high standard and the 
calibrator diluent, the zero standard (0 pg/mL). 
The assay diluent (100 μl) was added to each well of a plate, followed by the addition of 
50 μl of standard, control, or sample. The standards and samples were recorded on a template 
sheet. The plate was covered and incubated for 2 hours at room temperature on a horizontal 
orbital microplate shaker set at 500 rpm ± 50 rpm. Using an automatic washer, all wells were 
aspirated and washed for a total of four washes. The plate was then inverted and blotted 
against clean paper towels to remove any remaining solution from the wells. A volume of 200 μl 
of BMP-2 conjugate was added to each well. The plate was then covered and incubated for 
another 2 hours at room temperature on the same shaker. Four aspiration/wash cycles of the 
wells were performed. A volume of 200 μl of substrate solution was added to each well before 
a 30-minute incubation period while protected from light at room temperature on the 
benchtop. The Stop Solution (50 μl) was then added to each well. The optical density of each 
well was determined within 30 minutes, using a microplate spectrophotometerm. Optical 
densities were measured with the wavelength set at 450 and 570 nm. All measured values were 
entered into a spreadsheetn. To correct for optical imperfections in the plate, the readings at 
570 nm were subtracted from the readings at 450 nm. The average of the corrected duplicate 
readings for each standard, control, and sample was computed. The average zero standard 
optical density was then subtracted from each average. A standard curve was generated for 
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each set of samples assayed. A scatter plot of the optical density for the standards (y axis) 
versus the concentration of the standards (x axis) was made using a logarithmic axis (y axis) to 
make the relationship linear. A linear trend line was inserted in the plot. The equation of the 
linear function and its correlation coefficient (R2) were displayed. To determine the BMP-2 
concentration of each sample, the concentration value (x axis) was calculated for a given optical 
density, using the computed equation. If the samples were diluted, the concentration read from 
the standard curve was multiplied by the dilution factor. According to the manufacturer, the 
minimum detectable dose of BMP-2 ranged from 4.3 to 29 pg/mL (mean: 11 pg/mL). 
 
 Statistical analysis 
It was decided to perform this pilot in vitro experiment in order to better understand 
the binding of the drugs to and temporal release from the matrix. Due to financial constraints, it 
was not possible to have replication of the experimental unit (only 1 matrix specimen used per 
incubation period and drug assayed). Therefore, a statistical analysis was not performed. 
Descriptive data and graphical representation (concentration of tigecycline, tobramycin and 
rhBMP-2 vs. time) of the in vitro data is presented. 
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 IN VIVO EVALUATION OF THE NOVEL POLYMERIC BONE MATRIX AND 
EFFECT OF rhBMP-2 AND/OR ANTIMICROBIALS (TIGECYCLINE AND 
TOBRAMYCIN) IMPREGNATION ON BONE RESPONSE 
 Animals 
The animal model used in this study was approved by the Institutional Animal Care and 
Use Committee at the Kansas State University (protocol number 2619). Twenty skeletally 
mature (3 to 5 years old), clinically normal female crossbred goats were used in this study. The 
goats were determined to be healthy based on the results of physical and lameness 
examinations. Goats weighed a mean of 34.3 kg [75.5 lbs] (median, 34 kg [74.8 lbs]; range, 17-
50 kg [37.4-110 lbs]). All goats were allowed to have an acclimation period of 7 days and were 
housed in a group of 20 in a dry lot. During the early study period, all goats were housed in 
groups of 4 to 6 animals and housed in 12 feet X 12 feet [3.7 m x 3.7 m] stalls bedded with pine 
wood shavings (day 0 through day 17). On day 18 and through the completion of the study (day 
30), goats were housed in the dry lot. Goats were fed free choice brome hay and water 
throughout the study period except when food and water were withheld for 12 hours prior to 
surgery. The day of surgery was designated as day 0. 
 
 Anesthesia 
General anesthesia was induced in all goats using a combination of butorphanol 
tartrateo (0.025 mg/kg IV), xylazine hydrochloridep (0.05 mg/kg IV) and ketamine hydrochlorideq 
(2 mg/kg IV). Endotracheal intubation was performed and anesthesia maintained by the 
administration of isofluraner gas vaporized into 100% oxygen and delivered using a semi-closed 
circuit system. Surgical plane anesthesia was maintained by monitoring each goat for signs of 
spontaneous movement, response to surgical stimulation, palpebral reflex, heart rate, 
breathing rate, and mandibular muscle tone. 
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 Surgical procedures 
Following induction of general anesthesia, goats were placed in dorsal recumbency and 
the hind limbs attached to the surgery table in abduction and partial extension to allow access 
to the proximal and medial aspect of both tibias. A No. 40 surgical clipper blade was used to clip 
the hair of the medial surface of both hind limbs from the distal aspect of the femur to the mid-
diaphysis of the tibia. The clipped areas were aseptically prepared using alternating scrub cycles 
with iodine surgical scrub and 70% isopropyl alcohol. 
A 1.5-cm longitudinal skin incision was performed over the craniomedial aspect of the 
proximal diaphysis of the tibia using a No. 10 scalpel blade. The incision was extended through 
the periosteum. A 3.5-mm drill bit was inserted through a 3.5-mm tissue protector and drill 
guide and was drilled through the cis cortex of the tibia. A battery powered, low-speed (< 150 
rpm) drill was used to create the defects. One unicortical defect was created in each tibia. Using 
a Latin Square Design, the goats were completely blindly and randomly assigned to each of the 
five treatment groups consisting of 4 goats. The bone defect was created but not treated in the 
control group (group 1 (C)). In the other 4 treatment groups, the bone defect was created and 
then treated with matrix in group 2 (M), antimicrobial impregnated matrix in group 3 (MAb), 
rhBMP-2 impregnated matrix in group 4 (MBMP), or antimicrobial and rhBMP-2 impregnated 
matrix in group 5 (MAbBMP). After implantation of the matrix (groups 2, 3, 4, and 5), 
periosteum was apposed with No. 2-0 synthetic absorbable suture material and the skin 
incision was closed with No. 1 synthetic absorbable suture material in interrupted cruciate 
patterns. The closure of the periosteum and skin incisions was identically performed for group 
1. The procedure was repeated on the contralateral tibia. Both tibias of each goat were 
bandaged and animals were allowed to recover from anesthesia in a transporting pen with 
rubber flooring until they were able to stand and walk on their own. They were then returned 
to their original stall. 
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 Impregnation of antimicrobials and rhBMP-2 
All surgeries were performed on a total of four mornings. Tigecycline is stable at room 
temperature for up to 6 hours following reconstitution, therefore a new vial was reconstituted 
on each day of surgical implantations. Similarly, reconstituted rhBMP-2 is stable at room 
temperature for several hours and therefore a new vial was reconstituted each morning of 
surgical implantations.  
Intra-operative instillation of tigecycline, tobramycin and rhBMP-2 solutions onto the 
bone matrix was performed within 10 minutes of implantation using a sterile tuberculin syringe 
and needle. All products were distributed uniformly across the entire matrix. For group 5, the 
rhBMP-2 was instilled before the antimicrobials to ensure adequate impregnation. 
 
 Postoperative monitoring 
Complete physical examinations were performed every 12 hours for a period of 17 days 
after surgery on all goats and included the assessment of pain, lameness, and evaluation of the 
surgical site. Appetite, water intake, temperament, activity level, and interactions between the 
goats were also monitored. Bandages were removed 24 hours postoperatively. On day 14, the 
skin sutures were removed. Beginning on day 17 and continuing through day 30, the goats were 
visually inspected once daily to assess appetite, temperament, and behavior. 
All goats were allowed to walk and trot in a circle in their stall for lameness evaluation. 
Hind limb lameness was subjectively assessed twice daily on a scale of 0 to 4 (0 = normal gait; 1 
= mild lameness; 2 = moderate lameness; 3 = severe lameness; 4 = catastrophic lameness)93 for 
the first 17 days after surgery. Assessment was performed by the author who was blinded to 
treatment allocation. Based on initial statistical modeling analysis, the lameness scores were 
subsequently categorized as “0” for normal gait (previous lameness score of 0), and “1” for 
presence of lameness (previous lameness scores ≥ 1). This was done in order to transform the 
response variable (lameness) into a binomial distribution. The lameness data was modeled into 
a generalized linear model and analyzed using the GLIMMIX procedure in statistical analysis 
softwares. 
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 Radiographic evaluation of bone healing 
Radiographic images of the tibias were obtained every 2 weeks beginning the day after 
surgery (day 1, 14, 30). These images were obtained with the goats under recumbent sedation 
(xylazine hydrochloridep 0.05 mg/kg IV). If needed, sedative effects of the xylazine were 
reversed by subcutaneous injection of tolazoline hydrochloridet (1.5-2.0 mg/kg) at the end of 
the procedures. Two orthogonal radiographic views (lateral and craniocaudal) of each tibia 
were obtained using a digital radiography unitu and viewed via a computer software programv. 
Bone response surrounding the defects was assessed in two regions: periosteum, and 
endosteum. For statistical analysis, a subjective scoring system (0 = no reaction; 1 = presence of 
reaction) was used to assess bone response. A second scale was used to assess presence of 
excessive bony reaction (2 = absence of excessive reaction; 3 = presence of excessive reaction) 
in the two regions. On day 1, all scores were assigned a value of 0, and all subsequent images 
(days 14 and 30) were compared to the day 1 radiographs. Artifacts associated with the 
implanted matrix were taken into account when evaluating subsequent radiographs (days 14 
and 30). All images were evaluated at the end of the study by a reviewer that had been blinded 
to the treatment groups.  The response variables (periosteal and endosteal reactions) were 
modeled into a generalized linear model with a binomial distribution (GLIMMIX procedures). 
Significance was set at a P value of < 0.05.  
 
 Evaluation of bone mineral density 
Dual energy x-ray absorptiometry (DEXA) was used to quantitatively measure bone 
mineral density (BMD) at the site of implantation of the left tibia only. The procedure was 
performed on days 1, 14, and 30 under recumbent sedation protocol as previously described. 
Scans were performed at 140 and 70 kVP and a mean of 2.0 mA. Scans were performed in 
planes perpendicular to the long axis of the bone defect using a single beam with line spacing 
and point resolution set at 0.10 cm. A region of interest (ROI) 30 mm x 30 mm in area was 
defined centered on the bone defect. The ROI was then processed to create a bone map which 
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measured the area (cm2) and bone mineral content (grams), and calculated the BMD 
(grams/cm2). Due to the mineral component of the bone matrix, the initial BMD was measured 
postoperatively on day 1. A proportional change in BMD (Figure B.3) between days 1 and 14, 
and days 1 and 30 were then computed by subtracting the initial BMD (day 1) from the BMD on 
a given day (14 or 30) and dividing this change in BMD by the initial BMD (day 1). 
Proportional changes in BMD on days 14 and 30 were compared between treatment 
groups by performing an analysis of variance (ANOVA) of repeated measuresw. The variable 
“goat” was modeled as a random effect (repeated measures) and the variables “treatment 
groups” and “time” were modeled as fixed effects. Significance was set at a P value of < 0.05. 
 
 Collection and processing of blood samples 
A venous blood sample (8-10 ml) was collected from the jugular vein before the surgery 
(day 0) and at days 1, 2, 3, 4, 5, 6, 7, 9, 11, 13, 15, 17, 22, 26, and 30 after the implantation. 
Blood samples were transferred immediately from the syringe into a 10-ml serum tubex and a 
2-ml ethylenediaminetetraacetic acid (EDTA) coated tubey and stored on ice for up to 4 hours. 
Clotted blood samples were centrifugedz at room temperature for 10 minutes at 5000 rpm 
(1398 x g) to separate serum (serum tube) and plasma (EDTA tube) from the remaining blood 
components. Serum and plasma were collected, placed in cryotubes, and frozen at -80oC until 
rhBMP-2 assays (serum) or tigecycline and tobramycin assays (plasma) were performed. 
 
 Determination of plasma concentrations of tigecycline and tobramycin using 
LC/MS/MS 
Frozen plasma samples were thawed at room temperature. The analyte and internal 
standard were isolated from goat plasma. The same LC/MS/MS methods were used to 
determine plasma concentration of tigecycline and tobramycin as the ones used to measure 
supernatant concentrations. Only plasma samples from goats in groups 3 (MAb) and 5 
(MAbBMP) were analyzed. 
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Tigecycline and tobramycin plasma concentrations were compared between treatment 
groups using an ANOVA of repeated measuresw to determine presence or absence of time 
effect, treatment effect, and time and treatment interaction. The variable “goat” was modeled 
as a random effect (repeated measures) and the variables “treatment” and “time” were 
modeled as fixed effects. Significance was set at a P value of < 0.05. When a treatment effect or 
an interaction between time and treatment was detected, individual pair-wise comparisons of 
least squares means was performed using Student’s t-testw. 
 
 Determination of serum concentrations of rhBMP-2 by sandwich ELISA 
Concentration of rhBMP-2 in the serum samples was measured with a commercial 
rhBMP-2 ELISA kitl, as described for the in vitro study. Serum samples from goats in all groups 
were analyzed. Data was also analyzed using an ANOVA of repeated measures followed by 
Student’s t-test to compare least squares meansw. 
 
 Bone defect harvest and preparation of histological slides 
On day 30, all goats were euthanatized by intravenous injection of pentobarbital 
sodiumaa. Then, all tibias were harvested and 1 tibia per goat was randomly chosen for 
histological slide preparation and further histomorphologic analysis. After removal of the 
musculature surrounding the tibia, the bone defect was localized and sections of bone were 
prepared by cutting the tibia transversally about 1 cm proximal and distal to the bone defect. 
Sections of bone were preserved and shipped to an external laboratorybb in a 10% buffered 
formalin solution. 
Histological slides were prepared from non-decalcified bone sections containing the 
defect with implant in situ. Bone specimens were dehydrated in 70-100% ethanol solutions in 
multiple cycles for various amount of time (6 to 34 hours), then infiltrated and embedded with 
histological resincc. Specimens were sectioned with a commercial cutting and grinding systemdd 
and stained with toluidine blue O. Sections were obtained in a transverse plane, perpendicular 
to the long axis of the bone, and traveling through the bone defect and implant in situ. 
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 Histomorphologic analysis 
Three methods were used to evaluate the quantity of the bony response to the bone 
trauma and matrix. First, a subjective gross evaluation of the periosteal and endosteal reactions 
was performed with a reviewer blinded to the treatment groups. A subjective scoring system 
was used (1 = none or minimal reaction, 2 = moderate or marked reaction). The response 
variables (periosteal and endosteal reactions) of the gross evaluation of the histological slides 
was modeled into a generalized linear model with a binomial distribution using the GENMOD 
procedures. The probability that the endosteal and periosteal reactions were absent or minimal 
for each treatment groups was also computed. 
Secondly, a qualitative gross evaluation of the periosteal and endosteal reactions was 
performed. Using a digital caliper with a precision of 10 micrometers, the width and length of 
the periosteal reaction were measured from each histological slide. The surface area (mm2) of 
the bone reaction was computed by multiplying its width by its length. The procedure was 
repeated for the endosteal reaction surface. Furthermore, the width and length of the 
medullary cavity was measured and its surface area was similarly computed. An estimation of 
the medullary cavity surface covered by endosteal reaction was computed by dividing the 
estimated surface of endosteal reaction by the estimated surface of medullary cavity 
(ENDOS:MC ratio). Surfaces of periosteal and endosteal reactions as well as ENDOS:MC ratios 
were compared between treatment groups using a 1-way ANOVAw. When a significant 
difference was found, pair-wise comparisons of least squares means were performed using 
Student’s t-testw. 
Computerized images of the cortical defects seen on the histological slides were taken 
via light microscopyee coupled to a digital cameraff at 2X magnification.  Using image analysis 
softwaregg, the computerized images were split into red, green, and blue channeled images to 
allow further analysis. For the red channeled images, an area of interest was defined on the 
approximate margins of the cortical defect. The system then processed the image to measure 
the surface of the area of interest (μm2), and calculated the percent of the area that was filled 
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with bone and/or matrix. The procedure was repeated for the green and blue channeled 
images. The protocol used for this software is described in Appendix C. For each set of 
channeled images (red, green, and blue), the effect of treatment groups was analyzed using a 1-
way ANOVAw. The level of significance was P < 0.05. When significance was reached, pair-wise 
comparisons were done between all treatment groups using Student’s t-testw. 
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Chapter 3 - Results 
 IN VITRO EXPERIMENT 
 In vitro elution of tigecycline 
The greatest tigecycline elution was at the beginning of the experiment for the 
antimicrobials impregnated matrix (49,800 ng/ml). The day 1 sample for the co-impregnated 
matrix was lost and was not included in the data set. The elution of tigecycline from the 
antimicrobial impregnated and the co-impregnated matrix slowly decreased throughout the 
study period (Figures B.4 and B.5) and the smallest concentration was detected on day 30 (248 
ng/ml and 360 ng/ml, respectively; Table A.1). 
 
 In vitro elution of tobramycin 
The greatest tobramycin concentration was measured at the beginning of the 
experiment for the antimicrobial impregnated matrix (125,000 ng/ml). There was a missing 
sample from day 1 and insufficient sample volume in a sample from days 2 and 3. These data 
points were not included in the analysis. The tobramycin elution from the antimicrobial 
impregnated matrix and co-impregnated matrix rapidly decreased until day 8 at which time the 
elution slowly decreased until the end of the experiment to concentration of 23.4 ng/ml and 6.1 
ng/ml, respectively, on day 30 (Figures B.6 and B.7; Table A.1). 
When comparing the supernatant concentrations of tigecycline and tobramycin, the 
concentration of tigecycline was greater than that of tobramycin at all time points (Table A.1). 
 
 In vitro elution of rhBMP-2 
The greatest rhBMP-2 elution was at the beginning of the experiment for the rhBMP-2 
impregnated matrix (922,800 pg/ml; day 1). It was not possible to measure the rhBMP-2 elution 
from the co-impregnated (rhBMP-2 and antimicrobials) matrix due to the missing sample (day 
1). The rhBMP-2 elution from the co-impregnated matrix remained relatively constant from day 
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4 and throughout the experiment (Figure B.8). This is in contrast with the supernatant 
concentration of rhBMP-2 that suddenly increased on days 13 (298,880 pg/ml) and 15 (450,880 
pg/ml). For all time points, the concentration of rhBMP-2 in the supernatant of the rhBMP-2 
impregnated matrix was greater than that for the co-impregnated matrix (Table A.1). 
 IN VIVO EXPERIMENT 
 Surgical procedures and postoperative monitoring 
All surgical procedures and recoveries were uneventful. It was noted that the 
consistency of the polymeric matrix was variable between samples. Subjectively, insertion of 
the matrix within the bone defects was uneventful when the matrix kept its integrity. Insertion 
was found to be more difficult to realize due to breakage of the matrix in other goats. 
Physical examination parameters, appetite, water intake, temperament, activity level, 
and interactions between the goats remained within normal limits throughout the study period 
in all groups. The statistical modeling used for lameness score analysis did not converge; 
therefore descriptive statistics are used here. Lameness (score ≥ 1) from at least one hind limb 
was detected on all goats at least once during the study (Tables A.2 to A.6), with the majority of 
goats having multiple episodes of unilateral or bilateral lameness within the first 7 days of the 
study period. Only 4 goats (2 from group 1, one from group 2, and one from group 3) had a 
lameness affecting only one hind limb detected at less than four time points. Lameness was 
detected at a total of 233 time points from which 80.7% (188/233) were of score 1, 15.4% 
(36/233) of score 2, and 3.9% (9/233) of score 3. 
 
 Radiographic evaluation 
The loss of radiographic images from all goats in groups 2 and 3 was caused by digital 
data corruption. It was not possible to perform statistical analysis on data from day 14. On day 
30, no significant differences were detected among treatments for all radiographic scores 
evaluated (periosteal reaction, endosteal reaction, excessive periosteal reaction, and excessive 
endosteal reaction; P = 0.986, 0.760, 0.180, and 0.870, respectively; Table A.7). 
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 Bone mineral density 
On day 1, the mean BMD was 0.701 g/cm2, 0.585 g/cm2, 0.814 g/cm2, 0.695 g/cm2, and 
0.931 g/cm2 for groups 1, 2, 3, 4, and 5, respectively (Table A.8). On day 14, the mean BMD was 
0.629 g/cm2, 0.513 g/cm2, 0.828 g/cm2, 0.571 g/cm2, and 0.803 g/cm2 for groups 1, 2, 3, 4, and 
5, respectively (Table A.8). On day 30, the mean BMD was 0.603 g/cm2, 0.632 g/cm2, 0.900 
g/cm2, 0.597 g/cm2, and 0.810 g/cm2 for groups 1, 2, 3, 4, and 5, respectively (Table A.8). On 
days 14 and 30, the percent change in BMD did not differ significantly among the groups (P = 
0.864) and days (P = 0.362). 
 
 Plasma concentrations of tigecycline and tobramycin 
Statistical analysis revealed a significant change in mean plasma concentrations of 
tigecycline over time (P < 0.0001) for groups 3 (MAb) and 5 (MAbBMP). Treatment effect was 
not significant (P = 0.396), and a no significant interaction between time and treatment (P = 
0.653) was found. The results are represented with a single curve (Figure B.12) due to the 
absence of treatment and interaction effects. The highest mean plasma concentration of 
tigecycline (3.8 ± 0.3 ng/ml) was noted on day 1. The mean plasma concentration of tigecycline 
achieved a relative plateau at approximately 3.0 ng/ml on day 2 until day 17 before slowly 
decreasing until the end of the study period. A mean of 0.974 ± 0.270 ng/ml of tigecycline, 
which is below the minimal level of quantification (1.0 ng/ml), was detected at the end of the 
experiment (day 30; Table A.11). 
Statistical analysis revealed a significant change in mean plasma concentration of 
tobramycin over time (P < 0.0001) and a significant interaction between time and treatment (P 
= 0.0001). However, no treatment effect was detected (P = 0.074). The results are represented 
with two curves (Figure B.13) to demonstrate the different effect of time for both treatment 
groups (interaction). In group 3 (MAb), mean plasma concentrations of tobramycin between 
day 1 and day 4 were constant with values between 1.9 ± 0.6 and 2.0 ± 0.5 ng/ml. The peak 
concentration was delayed for group 3 (MAb) as compared to group 5 (MAbBMP). In fact, the 
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mean plasma concentration of tobramycin was the highest on day 1 (4.9 ± 0.4 ng/ml) and day 6 
(5.0 ± 0.4 ng/ml) for groups 5 (MAbBMP) and 3 (MAb), respectively (Table A.11). The mean 
plasma concentration of tobramycin remained constant between day 7 and day 26 in group 5 
(MAbBMP) with mean values between 2.4 ± 0.5 and 2.7 ± 0.5 ng/ml. However, mean plasma 
concentrations of tobramycin in goats of group 3 (MAb) slowly decreased to a mean of 1.6 ± 0.5 
ng/ml at the end of the study period (day 30; Table A.11). 
 
 Serum concentration of rhBMP-2 
Statistical analysis revealed a significant change in serum concentration of rhBMP-2 over 
time (P < 0.0001) and a significant interaction between time and treatment (P < 0.0001). 
However, no treatment effect was detected (Figure B.12; P = 0.402) between the five treatment 
groups (C, M, MAb, MBMP, MAbBMP). The two highest serum concentrations of rhBMP-2 were 
detected on day 7 in group 1 (C; 111.2 ± 8.0 pg/ml) and day 22 in group 3 (MAb; 111.0 ± 7.9 
pg/ml) and were significantly higher than mean pre-implantation values (day 0) of all groups. 
Initially, the rhBMP-2 concentration detected in the serum rapidly declined over the course of 3 
days (groups C, M, MAb, and MBMP) or 4 days (group MAbBMP) post-implantation to achieved 
concentrations between 15.3 and 23.4 ± 7.9 pg/ml. A rapid increase in the serum concentration 
was then measured until days 5 to 7 in all groups (concentrations between 93.9 and 111.2 ± 7.9 
pg/ml). This was followed by a sudden decrease and achievement of a relative plateau serum 
concentration of rhBMP-2 for all groups from day 9 to the end of the study (day 30) with values 
between 28.1 and 61.5 ± 7.9 pg/ml (Table A.15; Figure B.14). 
 
 Histomorphologic analysis 
No treatment effect was found for the amount of periosteal reaction determined by 
subjective gross evaluation of histological slides due to non convergence of the statistical model 
(Table A.17). Subjective gross evaluation of the endosteal reaction as seen on histological slides 
was significantly different between treatment groups (P = 0.0032; Table A.18). 
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Mean surface area of the periosteal reaction was significantly greater in group 4 (70.76 
± 10.97 mm2; P = 0.03) as compared to groups 1 (28.98 ± 10.97 mm2), 2 (26.65 ± 10.97 mm2), 
and 3 (16.92 ± 10.97 mm2), but was similar to mean surface of periosteal reaction surrounding 
unicortical defect of goats from group 5 (41.62 ± 10.97 mm2; Table A.20; Figure B.15).  
Mean surface area of endosteal reaction was significantly greater in group 4 (95.30 ± 
5.79 mm2; P < 0.0001) than the other groups, whereas mean surface area of endosteal reaction 
was significantly lower in group 1 (0.89 ± 5.79 mm2; Table A.20; Figure B.15). Surface area of 
ENDOS:MC ratio was larger in group 4 (0.6454 ± 0.0732 mm2; P = 0.0002) than groups 1 (0.0072 
± 0.0732 mm2) and 5 (0.3970 ± 0.0732 mm2). Group 1 also had a significantly lower ratio than 
any other groups (Table A.20; Figure B.16).  
Statistical analysis of the red and green channeled images revealed no significant 
treatment effect on the mean percent of filled bone defect (P = 0.2981, and 0.1598, 
respectively; Table A.26; Figure B.17). There was a significant difference between treatment 
groups (P = 0.0160) with the blue channeled images of the cortical defect (Figures B.18). The 
percent filling was greater in group 2 (M) than groups 1 (C) and 4 (MBMP) and similar to groups 
3 (MAb) and 5 (MAbBMP). 
Microscopic scanning of all histological slides did not reveal any signs of inflammation or 
infection. 
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Chapter 4 - Discussion 
 Bone healing in presence of the matrix 
Based on the results of this study, the novel polymeric bone matrix successfully 
stimulated bone healing and served as an effective drug delivery device. This novel polymeric 
bone matrix contained components, including demineralized bone matrix and hydroxyapatite, 
that are expected to enhance bone healing. Demineralized bone matrix has been shown to 
have osteoinductive characteristics due to numerous growth factors made available during 
dissolution of the inorganic matrix of bone98. Hydroxyapatite has been shown to have 
osteoconductive and perhaps osteostimulatory characteristics in bone99. Various polymers have 
been investigated for use as bone drug delivery devices for growth factors and antimicrobials, 
not always with success. Polymers may have a positive effect by delivering drugs of benefit to 
tissue healing99. Polymers may also have an inhibitory effect by interfering with tissue 
ongrowth and ingrowth into the defect100. In our goat model, the novel polymeric bone matrix 
stimulated significantly more new bone formation, as compared to the control group. This 
effect was greatly enhanced by the presence of rhBMP-2. Interestingly, the effect of the 
rhBMP-2 seemed to be moderated somewhat by the presence of tigecycline and tobramycin. 
This may have been caused by competitive binding of the various drugs or may have been 
associated with local inhibition of osteoblasts. 
 
 Elution kinetics 
Based on the results of the preliminary in vitro experiment, the novel polymeric bone 
matrix is a potential drug-delivery system for tigecycline, tobramycin and rhBMP-2. Elution was 
characterized by a rapid release of both antimicrobials studied during the first 24 hours 
followed by a slower elution rate during the following 30 days. The initial rapid release was 
probably due to the presence of the unbound proteins on the surface100 and within the 
micropores of the matrix. These molecules entered into solution almost immediately on 
immersion. 
25 
 
Elution of tigecycline from the novel polymeric bone matrix was similar to that reported 
from a nanoparticle composite100. The release kinetics of tobramycin were similar to that 
reported in other in vitro studies of non-biodegradable and biodegradable carriers (Table A.28). 
Although statistical analysis was not possible due to the absence of sample replication, 
presence of rhBMP-2 co-impregnated with antimicrobials did not appear to change the release 
kinetics of the antimicrobials in our study. The release kinetics of rhBMP-2 was also similar to 
those reported in other rhBMP-2 elution studies from biodegradable synthetic polymers101, 
composites102 and implant coatings103,104 under in vitro conditions.  
Drug release from a carrier system depends on numerous factors, such as the area of 
exposure, dissolution pattern, distribution within the matrix, and type of bond it forms on the 
carrier’s surfaces100, 105, 106. In our in vitro experiment, co-impregnation with antimicrobials 
appeared to change the elution of rhBMP-2 and this may have been associated with 
competitive binding in the matrix. However, sustained release of rhBMP-2 was achieved in the 
presence of antimicrobials. In fact, results from in vitro studies indicated that exogenous 
growth factors, such as rhBMP-2, should be delivered locally during a suitable period to allow 
complete osteoblastic differentiation of mesenchymal cells107,108.  
Comparison between in vitro and in vivo release profiles of rhBMP-2 is difficult because 
the in vivo release and retention mechanisms involve aqueous hydrolysis as well as enzymatic 
and cellular events, whereas in vitro elution is largely based on aqueous hydrolysis108-110. 
Bioactivity retention of rhBMP-2 was evaluated during the in vivo experiment; however, 
antimicrobial activity retention of tigecycline and tobramycin were not investigated. A change 
in carrier material can change the pharmacokinetics and effectiveness of the BMPs111 and 
antimicrobials. New bone formation was adequately produced in presence of the rhBMP-2-
impregnated matrix which confirmed the conservation of osteoinductive properties of rhBMP-
2. 
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 Choice of antimicrobials 
The most frequent bacterial pathogens implicated in chronic osteomyelitis in humans 
are the Gram-positive pathogens Staphylococcus aureus and group A β-hemolytic 
Streptococcus, and the Gram-negative pathogens such as Salmonella spp., Mycobacterium 
tuberculosis and Pseudomonas aeruginosa111. Antimicrobials most often selected based on 
desired spectrum for these organisms include aminoglycosides, β-lactams, and 
fluoroquinolones. These classes of drugs are widely studied antimicrobials for local delivery to 
bone 1, 112-114. Recently, in vitro activity of novel antimicrobial classes such as glycylcyclines (e.g. 
tigecycline), oxazolidinones (e.g. linezolid), and cyclic lipopeptides (e.g. daptomycin) against 
various clinical strains of resistant staphylococci isolated from bone infections have been 
tested. All isolates were susceptible to tigecycline except one methicillin-resistant 
Staphylococcus epidermidis isolate2. Moreover, in vitro elution studies of these new anti-
infective drugs in relation to various local delivery devices, studies on their antimicrobial 
efficacy when locally delivered to the bone, and local toxicity studies are limited115. 
Antimicrobial drugs selected for use in local delivery systems should be active against the most 
common bacterial pathogens involved in osteomyelitis, have a limited systemic absorption, 
have no toxic effects on cells involved in healing (e.g. endothelium, osteoblasts, osteoclasts, 
fibroblasts, etc), be safe to use (no adverse effects), be stable at normal body temperature, and 
be hydrosoluble for adequate diffusion from the carrier70,101,116. 
Tigecycline is the only marketed member of the new glycylcycline family of 
antimicrobials2. This semisynthetic bacteriostatic drug received approval for complicated skin 
and skin structure infections, complicated intra-abdominal infections, and community-acquired 
bacterial pneumonia from the FDA in 2005f,117. The molecular structure of tigecycline is 
characterized by the addition of a t-butylglycylamido group at the C-9 position on the central 
skeleton of minocycline117 which confers an extended spectrum of activity (Gram-positive and 
Gram-negative aerobic bacteria and anaerobic and atypical bacteria, including resistant 
microorganisms) as compared to other tetracyclines. Tigecycline has limited activity against 
Pseudomonas aeruginosa and Proteus mirabilis117. It acts by inhibiting protein synthesis in 
susceptible microorganisms by binding to receptors on the 30S subunit of the bacterial 
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ribosome preventing the addition of amino acids to the elongating peptide chain118. Tigecycline 
has been reported to be effective in the systemic treatment of methicillin-resistant 
Staphylococcus aureus-induced tibial osteomyelitis in a rabbit model117. Tigecycline was chosen 
in our study because of its large spectrum of activity including multi-resistant bacteria as well as 
its potential to treat osteomyelitis in complicated fractures in humans. 
Tobramycin is an aminoglycoside structurally related to kanamycin with bactericidal and 
pharmacokinetic properties similar to gentamicin. It has dose (concentration) dependent 
activity primarily against aerobic, Gram-negative bacteria. It has been estimated to have up to 
four times the activity of gentamicin against Pseudomonas spp.119, which is a significant 
addition to the spectrum of activity of tigecycline. Tobramycin acts by bacterial ribosomal 
binding of the 30S and 50S subunits. Due to the resulting prevention of formation of the 70S 
complex, mRNA cannot be translated into protein. Relative risk for acute renal tubular necrosis, 
and cochlear and vestibular toxicities appear slightly decreased with systemic usage of 
tobramycin as compared to other aminoglycosides such as gentamicin and kanamycin120. 
Over the years, researchers have employed various classes of antimicrobials to locally 
deliver bactericidal concentrations of drugs to normal or affected bone using in vivo models and 
clinical patients. A combination of tigecycline and tobramycin was chosen in our study for 
multiple reasons. Tobramycin represents a commonly used aminoglycoside and is widely used 
for local delivery to bone of human patients in the United States because of its spectrum of 
activity and its availability as a powder121. It has been shown to be efficient at concentrations 
that are not toxic to bone cells1,2,122,123. Tigecycline has shown promise with treatment of 
infected bone in animal models3,122. Furthermore, tigecycline has an enhanced spectrum of 
activity against resistant pathogens115 involved in clinical cases of osteomyelitis in humans. 
 
 Local bone toxicity of antimicrobials 
Concerns have been raised regarding the in vitro effect of tigecycline on human 
osteoblast viability in culture. Concentrations of 10 µg/ml appeared to suppress osteoblast cell 
proliferation124-126. In our study, we were not able to investigate the local concentrations of 
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tigecycline achieved in the interstitial fluids surrounding bone defect after implantation of the 
matrix. The effect of different concentrations of tigecycline on local bone metabolism as well as 
surrounding tissues has not been reported in the literature to the author’s knowledge. 
Local delivery of aminoglycosides have been reported to achieve local concentrations 
that are > 600 times what is considered toxic in serum without developing systemic toxicity or 
side effects127. However, the result of an experimental study on the effects of tobramycin on 
human osteoblast-like cells and rat osteoblasts demonstrated that local levels of 400 µg/ml 
significantly reduced osteoblast replication, and concentrations of 10,000 µg/ml caused cell 
death; but concentrations ≤ 200 µg/ml had minimal to no effect on cell replication128. Another 
study found that tobramycin at doses > 2000 µg/ml severely decreased cellular proliferation of 
osteoblasts and chondrocytes122. In our study, the peak concentration of tobramycin eluted 
from the matrix during the preliminary in vitro experiment was 125 µg/ml. This concentration 
likely overestimates the concentration that would be achieved at the implantation site because 
of interstitial fluid fluxes, and is expected to have little to no effect on replication of 
osteoblasts.  
 
 Systemic exposure to tigecycline and tobramycin 
Systemic exposure to tigecycline was minimal in our goat model. According to the 
product insertf, the maximal serum concentration of tigecycline is between 0.63 and 1.45 µg/ml 
and the minimal trough serum concentration of tigecycline at 12 hours is 0.13 µg/ml after 
intravenous administration of 100 mg in humans. By comparing these pharmacokinetic 
parameters to the mean maximal serum concentration (day 1) in our model, we can conclude 
that the peak serum concentration was approximately 32 times lower than the expected 
minimum serum concentration after parenteral administration in humans. Hence, tigecycline 
concentrations did not reach therapeutic range systemically and toxicity was consequently 
avoided. 
Monitoring of serum concentrations of aminoglycosides to reduce toxicity and confirm 
therapeutic concentrations has been described in human129 and veterinary130,131 medicine. 
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Elevated trough concentrations is one of the risk factors for aminoglycoside toxicity132. It is 
thought that trough concentrations of tobramycin greater than 5 µg/ml contribute to 
nephrotoxicity133. Since the highest serum concentration of tobramycin was 4.9 ± 0.4 ng/ml, 
systemic exposure to tobramycin was low and toxic concentrations were not reached 
systemically in this caprine model. 
 
 Systemic exposure to rhBMP-2 
According to the product insertl, the rhBMP-2-specific sandwich ELISA kit utilized 
recognizes recombinant and natural BMP-2 from human, rat, and mouse serum. This assay has 
not been validated for use with goat serumhh. Cross-reactivity of the test for different species 
rhBMP-2 is expected to be good when a similarity of > 80% in the amino acids composing BMP-
2 molecule occurhh. It is well established that the amino acid sequences of BMP-2 is highly 
evolutionarily conserved between species of mammals134. In a more recent study this finding 
was specifically confirmed for the BMP-2 protein sequences of three breeds of goats135. Hence, 
it is very likely that the similarity between the amino acid sequences of the caprine BMP-2 
molecule and the human BMP-2 is greater than 80%; therefore, the test used was most likely 
able to detect endogenous caprine BMP-2 molecules as found by the serum concentrations 
measured preoperatively from all groups, and in groups not treated by BMP-2- impregnated 
matrix. According to the manufacturer’s instructionl, a standard curve was constructed using 
known serial concentrations between 62.5 and 4000 pg/ml. Extrapolation of optical densities 
outside the standard curve can result in false detection of rhBMP-2. This is not a problem in the 
presence of high concentrations that can be diluted before performing the assay. In our study, 
most of the concentrations of BMP-2 measured were below the limit of the standard 62.5 
pg/ml. Thus, it is difficult to make conclusions as to the actual concentrations in these goats. 
Mean serum concentration of rhBMP-2 was found to be increased after surgery at two 
time points. Interestingly, these findings were from groups not treated with rhBMP-2- 
impregnated matrix (groups C and MAb). Possible explanations may reside in a sudden release 
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of endogenous BMP-2 from the bone trauma site, a cross reaction or interference with another 
molecule, or a technical error with the assay.  
Systemic and local toxic effects and adverse reactions associated with the use of rhBMP-
2 have not been observed in human or animal studies. This is most likely due to the short half-
life and rapid clearance of BMP-2 resulting in minimal systemic exposure136. 
 
 Compatibility between BMP-2 and antimicrobials 
The in vitro and in vivo compatibility of BMPs and antimicrobials have been previously 
investigated. Kawaguchi et al. found that the local delivery of tobramycin in aqueous solution or 
impregnated in PMMA beads does not affect the osteoinductive properties of rhBMP-7 in a rat 
model of ectopic bone formation137. Suzuki et al. reported that the local application of 
teicoplanin had no inhibitory effect on the ability of locally delivered rhBMP-2 to heal rat 
calvarial defects138. These two studies looked at ectopic and calvaria bone formation which 
occurs through intramembranous ossification whereas long bone healing occurs through 
endochondral ossification. Another study139 found a dose-dependent inhibition of alkaline 
phosphatase induction and calcium deposition by human mesenchymal stem cells cultured 
under osteogenic conditions. This inhibition was reversed with the addition of rhBMP-2 at the 
concentration of 500 ng/ml. During the in vivo experiment of that same study140, tobramycin 
did not impair the ability of rhBMP-2 to heal non infected critical-sized femoral defects in a rat 
model. The results of the study reported here are not in complete accordance with that study. 
Presence of tigecycline and tobramycin co-impregnated into the novel polymeric bone matrix 
appeared to have affected the ability of rhBMP-2 to enhance bone healing in this goat 
unicortical tibia defect as determined by a lower endosteal reaction surface area. However, 
based on the radiographic scores, BMD, and other histomorphologic parameters measured, 
presence of antimicrobials did not affect the BMP-2-induced new bone formation in vivo. 
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 Study limitations 
A limitation in the in vitro experiment was the absence of replication of the 
experimental unit which limited statistical analysis. Furthermore, even though local toxicity of 
the two antimicrobials used in this experiment has been tested, the local toxicity of the 
combination of both has not been evaluated. Additionally, the antimicrobial activity of the 
antimicrobials, individually or in combination, was not evaluated. 
Goats have been used as animal models for cartilage, meniscal and ligamentous repair, 
and for testing implantation of biomaterials in bone140. Caprine bone metabolic and remodeling 
rates141, 142 are similar to those of humans. Tibial blood supply of goats is also similar to the 
human tibial blood supply143, 144. Recommended dimensions of cylindrical implants in the 
caprine femur or tibia are 4 mm in diameter and 12 mm in length145. The tested implant in the 
present study had similar dimensions. A unicortical tibial defect model of suitable dimensions 
to accommodate the bone implant was used to test the novel polymeric bone matrix and was 
chosen as an initial test. In order to evaluate the full potential of this implant, a critical-sized 
cortical defect model (> 2 times the diaphyseal diameter) would be necessary. 
A relatively small number of goats (4) were allocated per treatment group. This probably 
resulted in our difficulties to detect significant differences between the treatment groups and 
discrepancy between the results of the different bone healing evaluation methods 
(radiographic evaluation, BMD assessment, and histomorphologic analysis). 
Another limitation in this in vivo experiment was the duration of the study period. At the 
end of the study period (30 days), the bone defects were not completely healed and the novel 
polymeric bone matrix was not completely absorbed. This resulted in difficulties to evaluate the 
quality and quantity of new bone formation. 
 
 Conclusions 
Based on the results of this study, the novel polymeric bone matrix served as an 
effective carrier for rhBMP-2. Defects treated with the matrix containing rhBMP-2 formed 
significantly more bone that that of controls and defects that contained only matrix or matrix 
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and antimicrobials. Interestingly, the matrix in all forms studied, stimulated greater endosteal 
new bone formation than controls. The matrix allowed release of antibiotics for at least 30 days 
after implantation. The elution curve was similar to other drug delivery devices with a rapid 
elution phase initially, followed by a relative plateau. Antibiotics and rhBMP-2 can be used in 
concert, but the presence of antibiotics may affect the performance of rhBMP-2. The novel 
polymeric bone matrix can serve as an excellent drug delivery system for the elution of 
antibiotics and growth factors. 
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Footnotes 
a. INFUSE Bone Graft, Medtronic Safamor Danek, Inc., Minneapolis, Minnesota, 55432. 
b. OP-1 Implant, Stryker Biotech, Hopkinton, Massachusetts, 01748. 
c. OP-1 Putty, Stryker Biotech, Hopkinton, Massachusetts, 01748. 
d. ORLUMET LLC., Little Rock, Arkansas, 72116. 
e. Nanotechnology Center, University of Arkansas at Little Rock, Little Rock, Arkansas, 72204. 
f. Tigacyl, Wyeth Pharmaceuticals, Inc., Philadelphia, Pennsylvania, 19101. 
g. Tobramycin Injection USP, SICOR Pharmaceuticals, Inc., Irvine, California, 92618. 
h. Ultrafree-MC Centrifugal Filter Units with Microporous Membrane, Millipore, Inc., Billerica, 
Massachusetts, 01821. 
i. Shimadzu HPLC system, Shimadzu North America / Shimadzu Scientific Instruments, Inc., 
Columbia, Maryland, 21046. 
j. Sciex API 4000 Triple Quadrupole Mass Spectrometer, AB SCIEX, Inc., Foster City, California, 
94404. 
k. XBridge Shield RP18 Column, Waters Corporation, Milford, Massachusetts, 01757. 
l. Quantikine BMP-2 Immunoassay, R&D Systems, Inc., Minneapolis, Minnesota, 55413. 
m. Spectra MAX 190, Molecular Devices, Sunnyvale, California, 94089. 
n. Microsoft Office Excel 2007, Microsoft Corporation, Redmond, Washington, 98052. 
o. Butorphic Injection, 10 mg/ml, LLOYD Laboratories, Inc., Shenandoah, Iowa, 51601. 
p. AnaSed Injection, 20 mg/ml, LLOYD Laboratories, Inc., Shenandoah, Iowa, 51601. 
q. KetaVed, 100 mg/ml, Vedco, St. Joseph, Missouri 64507. 
r. ISOFLURANE USP, Abbott Laboratories, Abbott Park, Illinois, 60064. 
s. SAS 9.1.3, SAS Institute, Inc., Cary, North Carolina, 27513. 
t. Tolazine Injection, 100 mg/ml, LLOYD Laboratories Inc., Shenandoah, Iowa, 51601. 
u. Rapid Study EDR3 Mark III, Eklin Medical Systems, Inc., Santa Clara, California, 95054. 
v. AGFA Web1000, Agfa Corporation, Ridgefield Park, New Jersey, 07660. 
w. JMP 8.0.1, SAS Institute, Inc., Cary, North Carolina, 27513. 
x. BD Vacutainer Serum, BD Diagnostics, Franklin Lakes, New Jersey, 07417. 
y. BD Vacutainer K2EDTA 3.6mg, BD Diagnostics, Franklin Lakes, New Jersey, 07417. 
z. International Clinical Centrifuge model CL, International Equipment Co., Needham Heights, 
Massachusetts, 02494.  
aa. Fatal-Plus, 390 mg/ml, Vortech Pharmaceuticals, Ltd., Dearborn, Michigan, 48126. 
bb. Purdue Histology and Phenotyping Laboratory, Hard Tissue Section, Medical Discovery and 
Research Unit, School of Veterinary School, Purdue University, West Lafayette, Indiana, 
47907. 
cc. Technovit 7200 VLC, Heraeus Kulzer GmbH, 61273 Wehrheim, Germany. 
dd. Exakt cutting-grinding system, EXAKT Technologies, Inc., Oklahoma City, Oklahoma, 73116. 
ee. Nikon Eclipse E600, Nikon Corporation Instruments Company, Tokyo, Japan. 
ff. Nikon Coolpix 995 with Coolpix MDC adaptor, Nikon, Inc., Melville, New York, 11747. 
gg. ImageJ 1.42q, Wayne Rasband, National Institutes of Health, http://rsb.info.nih.gov/ij, 
United States. 
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hh. Personnal communication with technical services, R&D Systems, Inc., Minneapolis, 
Minnesota, 55413. 
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Appendix A - Supplementary Tables 
Table A.1 In Vitro Elution Data of rhBMP-2, Tigecycline, and Tobramycin from the Novel 
Polymeric Bone Matrix, Days 0-30 
 
rhBMP-2 
impregnated 
matrix 
Antimicrobials impregnated 
matrix 
rhBMP-2 and antimicrobials impregnated matrix 
Time 
(days) 
rhBMP-2 [C] 
(pg/ml) 
Tigecycline [C] 
(ng/ml) 
Tobramycin [C] 
(ng/ml) 
rhBMP-2 [C] 
(pg/ml) 
Tigecycline [C] 
(ng/ml) 
Tobramycin [C] 
(ng/ml) 
1 922,880 49800 125000 . . . 
2 916,480 18500 28200 302,080 9960 . 
3 532,480 14600 5920 145,280 6950 . 
4 422,080 9650 1550 178,880 7890 859 
5 326,080 5960 891 153,280 4690 347 
6 276,480 4090 429 113,280 5700 . 
8 247,680 3280 267 143,680 5280 238 
10 156,480 1080 . 124,480 3170 117 
13 298,880 1210 70.8 159,680 2890 109 
15 450,880 818 71.2 121,280 2010 46.8 
17 193,280 797 38.4 108,480 1090 26.7 
21 199,680 475 32.8 119,680 1410 27.2 
25 202,880 379 51.5 121,280 811 40.1 
28 167,680 390 22.7 100,480 349 11.4 
30 130,880 248 23.4 116,480 360 6.1 
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Table A.2 Initial Hind Limb Lameness Scores for Goats in Group 1 (C), Days 0-17 
 
Goat 32 Goat 35 Goat 38 Goat 43 
Time Left Right Left Right Left Right Left Right 
D0 / AM 0 0 0 0 0 0 0 0 
D0 / PM 0 0 3 0 0 0 0 0 
D1 / AM 0 0 1 0 0 0 1 0 
D1 / PM 0 0 1 0 0 0 0 0 
D2 / AM 0 0 0 0 1 0 0 0 
D2 / PM 0 0 . . . . . . 
D3 / AM 1 0 1 0 0 0 0 0 
D3 / PM 1 0 1 0 0 0 0 0 
D4 / AM 2 0 2 0 1 0 . . 
D4 / PM 1 0 1 0 0 0 1 0 
D5 / AM 0 0 1 0 0 0 0 0 
D5 / PM 0 0 0 0 0 0 0 0 
D6 / AM 0 0 1 0 0 0 0 0 
D6 / PM 0 0 1 0 0 0 0 0 
D7 / AM 0 0 1 0 0 0 0 0 
D7 / PM . . 1 0 0 0 0 0 
D8 / AM 0 0 1 0 0 1 0 0 
D8 / PM . . . . 0 1 . . 
D9 / AM 0 0 0 0 0 0 0 0 
D9 / PM . . 0 0 0 0 0 0 
D10 / AM . . 0 0 0 0 0 0 
D10 / PM 0 0 0 0 0 1 . . 
D11 / AM 0 0 0 0 0 0 0 0 
D11 / PM 0 0 0 0 0 0 . . 
D12 / AM 0 0 1 1 0 0 0 0 
D12 / PM 0 0 1 1 0 0 0 0 
D13 / AM 0 0 0 0 0 0 . . 
D13 / PM . . 0 0 0 0 0 0 
D14 / AM 0 0 0 0 0 0 0 0 
D14 / PM 0 0 0 0 . . 0 0 
D15 / AM 0 0 0 0 0 0 . . 
D15 / PM 0 0 . . . . . . 
D16 / AM 0 0 0 0 0 0 . . 
D16 / PM . . . . . . . . 
D17 / AM . . 0 0 0 0 . . 
D17 / PM . . . . . . . . 
Legend: D = day; AM = morning evaluation; PM = evening evaluation; score 0 = normal gait; score 1 = mild 
lameness; score 2 = moderate lameness; score 3 = severe lameness; score 4 = catastrophic lameness. Please 
note that the initial lameness scores are presented here, before recoding them into code 0 = normal gait (initial 
score of 0) and code 1 = lameness score ≥ 1. 
46 
 
 
Table A.3 Initial Hind Limb Lameness Scores for Goats in Group 2 (M), Days 0-17 
 
Goat 42 Goat 44 Goat 47 Goat 48 
Time Left Right Left Right Left Right Left Right 
D0 / AM 0 0 0 0 0 0 0 0 
D0 / PM 1 2 0 0 0 2 0 1 
D1 / AM 0 0 1 0 3 0 0 0 
D1 / PM 0 0 . . 2 0 0 0 
D2 / AM 0 0 0 0 1 0 1 0 
D2 / PM . . 0 0 1 0 1 0 
D3 / AM 0 1 . . . . . . 
D3 / PM 0 1 0 0 3 0 0 1 
D4 / AM . . 0 0 2 0 1 0 
D4 / PM 0 0 0 0 3 0 0 1 
D5 / AM 0 0 0 0 3 0 0 0 
D5 / PM 0 0 0 0 2 0 0 0 
D6 / AM 0 1 0 0 2 0 0 0 
D6 / PM 0 0 0 0 3 0 0 0 
D7 / AM 0 0 0 0 2 0 0 0 
D7 / PM 0 0 . . . . . . 
D8 / AM 0 0 0 0 1 0 0 0 
D8 / PM . . . . . . . . 
D9 / AM 0 0 0 0 0 0 0 0 
D9 / PM 0 0 . . . . . . 
D10 / AM 0 0 . . . . . . 
D10 / PM . . 0 0 0 0 0 0 
D11 / AM 0 0 0 0 0 0 0 0 
D11 / PM . . 0 0 0 0 0 0 
D12 / AM 0 0 0 0 0 0 0 1 
D12 / PM 0 0 0 0 0 0 0 0 
D13 / AM . . 0 0 0 0 0 1 
D13 / PM 0 0 . . . . . . 
D14 / AM 0 0 0 0 0 0 0 1 
D14 / PM 0 0 0 0 0 0 0 1 
D15 / AM 0 0 0 0 0 0 0 1 
D15 / PM 0 0 0 0 0 0 0 0 
D16 / AM 0 0 0 0 0 0 0 0 
D16 / PM 0 0 . . . . . . 
D17 / AM 0 0 . . 0 0 . . 
D17 / PM . . . . . . . . 
Legend: D = day; AM = morning evaluation; PM = evening evaluation; score 0 = normal gait; score 1 = mild 
lameness; score 2 = moderate lameness; score 3 = severe lameness; score 4 = catastrophic lameness. Please 
note that the initial lameness scores are presented here, before recoding them into code 0 = normal gait (initial 
score of 0) and code 1 = lameness score ≥ 1. 
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Table A.4 Initial Hind Limb Lameness Scores for Goats in Group 3 (MAb), Days 0-17 
 
Goat 39 Goat 40 Goat 41 Goat 45 
Time Left Right Left Right Left Right Left Right 
D0 / AM 0 0 0 0 0 0 0 0 
D0 / PM 1 0 1 2 2 2 0 1 
D1 / AM 1 0 0 1 2 2 0 1 
D1 / PM 0 0 1 2 1 1 0 0 
D2 / AM 0 0 0 1 2 0 0 0 
D2 / PM . . . . . . 0 0 
D3 / AM 0 3 0 3 0 0 . . 
D3 / PM 0 2 0 2 0 0 0 0 
D4 / AM . . . . . . 0 0 
D4 / PM 0 0 0 2 0 0 0 0 
D5 / AM 0 0 0 1 0 0 0 0 
D5 / PM 0 0 0 2 0 0 0 0 
D6 / AM 0 0 0 1 0 0 0 0 
D6 / PM 0 1 0 3 0 0 0 0 
D7 / AM 0 1 0 2 0 0 0 0 
D7 / PM 0 0 0 2 0 0 . . 
D8 / AM 0 1 0 1 0 0 0 0 
D8 / PM . . . . . . . . 
D9 / AM 0 0 0 0 0 0 0 0 
D9 / PM 0 0 0 0 0 0 . . 
D10 / AM 0 0 0 0 0 0 . . 
D10 / PM . . . . . . 0 0 
D11 / AM 0 0 0 0 0 0 0 0 
D11 / PM . . . . . . 0 0 
D12 / AM 0 0 0 0 0 0 0 0 
D12 / PM 0 1 0 0 0 0 0 0 
D13 / AM . . . . . . 0 0 
D13 / PM 0 1 0 0 0 0 . . 
D14 / AM 1 0 0 0 0 0 0 0 
D14 / PM . . . . 0 0 0 0 
D15 / AM 0 0 0 0 0 0 0 0 
D15 / PM 0 0 0 0 0 0 0 0 
D16 / AM 0 0 0 0 0 0 0 0 
D16 / PM 0 1 0 0 0 0 . . 
D17 / AM 0 0 0 0 0 0 . . 
D17 / PM . . . . . . . . 
Legend: D = day; AM = morning evaluation; PM = evening evaluation; score 0 = normal gait; score 1 = mild 
lameness; score 2 = moderate lameness; score 3 = severe lameness; score 4 = catastrophic lameness. Please 
note that the initial lameness scores are presented here, before recoding them into code 0 = normal gait (initial 
score of 0) and code 1 = lameness score ≥ 1. 
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Table A.5 Initial Hind Limb Lameness Scores for Goats in Group 4 (MBMP), Days 0-17 
 
Goat 27 Goat 29 Goat 33 Goat 36 
Time Left Right Left Right Left Right Left Right 
D0 / AM 0 0 0 0 0 0 0 0 
D0 / PM 1 0 0 0 0 1 0 0 
D1 / AM 0 1 0 0 1 0 0 1 
D1 / PM 0 1 1 0 1 0 1 0 
D2 / AM 0 1 0 0 0 2 0 0 
D2 / PM . . . . 0 1 . . 
D3 / AM 0 1 0 1 0 2 0 0 
D3 / PM . . . . 0 2 0 2 
D4 / AM 1 1 0 0 0 2 0 2 
D4 / PM 0 2 0 0 0 2 0 2 
D5 / AM 0 0 0 0 0 0 0 2 
D5 / PM 0 1 0 1 0 1 2 0 
D6 / AM 0 1 0 0 1 0 0 2 
D6 / PM 0 0 0 1 0 2 0 1 
D7 / AM 0 1 0 1 0 1 0 1 
D7 / PM 1 0 0 1 0 1 0 1 
D8 / AM 0 1 1 0 0 0 0 1 
D8 / PM . . . . 0 0 0 1 
D9 / AM 0 0 0 0 0 0 0 0 
D9 / PM 0 0 0 0 0 0 0 0 
D10 / AM 0 0 0 0 0 0 0 0 
D10 / PM 0 0 0 0 0 0 0 0 
D11 / AM 0 0 . . 0 0 0 0 
D11 / PM 0 0 0 0 0 0 0 0 
D12 / AM 0 0 1 0 0 0 0 0 
D12 / PM 0 0 0 0 0 0 0 0 
D13 / AM 0 0 0 0 0 0 0 0 
D13 / PM 0 0 0 0 0 0 0 0 
D14 / AM 0 0 0 0 0 0 0 0 
D14 / PM 0 0 0 0 0 0 0 0 
D15 / AM 0 0 0 0 0 0 0 0 
D15 / PM . . . . . . . . 
D16 / AM 0 0 0 0 0 0 0 0 
D16 / PM . . . . . . . . 
D17 / AM 0 0 0 0 0 0 0 0 
D17 / PM . . . . . . . . 
Legend: D = day; AM = morning evaluation; PM = evening evaluation; score 0 = normal gait; score 1 = mild 
lameness; score 2 = moderate lameness; score 3 = severe lameness; score 4 = catastrophic lameness. Please 
note that the initial lameness scores are presented here, before recoding them into code 0 = normal gait (initial 
score of 0) and code 1 = lameness score ≥ 1. 
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Table A.6 Initial Hind Limb Lameness Scores for Goats in Group 5 (MAbBMP), Days 0-17 
 
Goat 18 Goat 30 Goat 34 Goat 37 
Time Left Right Left Right Left Right Left Right 
D0 / AM 0 0 0 0 0 0 0 0 
D0 / PM 1 0 0 0 1 0 0 0 
D1 / AM 1 0 0 0 0 0 1 0 
D1 / PM 0 1 1 0 0 0 0 0 
D2 / AM 1 1 1 0 0 1 0 1 
D2 / PM . . . . 0 0 . . 
D3 / AM 0 1 0 1 2 0 0 1 
D3 / PM . . . . 0 0 0 0 
D4 / AM 0 0 0 0 0 1 0 0 
D4 / PM 1 0 0 0 0 1 0 0 
D5 / AM 0 0 0 1 1 1 0 0 
D5 / PM 1 1 0 1 0 1 0 0 
D6 / AM 0 0 0 0 0 0 0 0 
D6 / PM 0 0 1 0 0 1 0 1 
D7 / AM 0 0 1 0 0 1 0 1 
D7 / PM 0 1 0 1 0 0 0 0 
D8 / AM 0 0 1 0 0 1 1 0 
D8 / PM 0 0 1 0 0 1 1 0 
D9 / AM 0 0 1 0 1 0 1 0 
D9 / PM 0 0 . . 1 0 1 0 
D10 / AM 0 0 0 0 0 0 1 0 
D10 / PM 0 0 0 0 0 0 1 0 
D11 / AM . . 0 0 0 0 0 0 
D11 / PM 1 0 0 0 0 0 1 0 
D12 / AM 1 0 1 0 0 0 0 0 
D12 / PM 1 0 0 0 1 0 0 0 
D13 / AM 1 0 1 0 0 0 0 0 
D13 / PM 0 0 0 0 0 0 0 0 
D14 / AM 0 0 0 0 0 0 0 0 
D14 / PM 0 0 0 0 0 0 . . 
D15 / AM 0 0 0 0 0 0 0 0 
D15 / PM . . . . . . . . 
D16 / AM 0 0 0 0 0 0 0 0 
D16 / PM . . . . . . . . 
D17 / AM 0 0 0 0 0 0 0 0 
D17 / PM . . . . . . . . 
Legend: D = day; AM = morning evaluation; PM = evening evaluation; score 0 = normal gait; score 1 = mild 
lameness; score 2 = moderate lameness; score 3 = severe lameness; score 4 = catastrophic lameness. Please 
note that the initial lameness scores are presented here, before recoding them into code 0 = normal gait (initial 
score of 0) and code 1 = lameness score ≥ 1. 
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Table A.7 Recoded Radiographic Scores of Healing Tibial Bone Defects in all Goats, Day 30 
Goat Endosteal reaction Periosteal reaction 
Excessive endosteal 
reaction 
Excessive periosteal 
reaction 
Group 1 
(C) 
Left Right Left Right Left Right Left Right 
32 1 1 1 1 2 2 2 2 
35 1 1 1 1 2 2 3 2 
38 0 1 0 1 2 2 2 2 
43 1 1 0 0 2 2 2 2 
Group 2 
(M) 
Left Right Left Right Left Right Left Right 
42 1 1 0 1 2 2 2 2 
44 1 1 1 0 2 2 2 2 
47 1 1 1 1 3 2 3 3 
48 0 1 0 1 2 2 2 2 
Group 3 
(MAb) 
Left Right Left Right Left Right Left Right 
39 1 1 1 1 2 2 2 3 
40 1 1 1 1 2 2 2 3 
41 1 0 0 0 2 2 2 2 
45 0 0 0 0 2 2 2 2 
Group 4 
(MBMP) 
Left Right Left Right Left Right Left Right 
27 1 1 1 1 2 2 2 2 
29 1 1 1 1 2 3 2 3 
33 1 1 1 1 3 3 3 3 
36 1 1 1 1 2 2 3 3 
Group 5 
(MAbBMP) 
Left Right Left Right Left Right Left Right 
18 1 1 1 1 3 3 3 3 
30 1 1 1 1 2 2 2 3 
34 1 1 1 1 2 2 2 2 
37 1 1 1 1 2 2 3 3 
Legend: Score 0 = none or minimal reaction; score 1 = moderate or excessive reaction; score 2 = absence 
of excessive reaction; score 3 = excessive reaction. 
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Table A.8 Bone Mineral Densities (BMD) and Proportional Change in BMD when Compared to 
Day 1 for all Goats, Days 1, 14, and 30 
Group 1 (C) BMD (g/cm
2
) Proportional change in BMD 
Goat Day 1 Day 14 Day 30 D14 - D1 D30 - D1 
32 0.434 0.407 0.433 -0.062 -0.002 
35 1.030 0.559 0.457 -0.457 -0.556 
38 0.326 0.514 0.428 0.577 0.313 
43 1.013 1.037 1.095 0.024 0.081 
Average 0.701 0.629 0.603 . . 
Group 2 (M) Day 1 Day 14 Day 30 D14 - D1 D30 - D1 
42 0.467 0.721 0.428 0.544 -0.084 
44 0.488 0.367 0.496 -0.248 0.016 
47 1.041 0.634 1.157 -0.391 0.111 
48 0.342 0.330 0.447 -0.035 0.307 
Average 0.585 0.513 0.632 . . 
Group 3 (MAb) Day 1 Day 14 Day 30 D14 - D1 D30 - D1 
39 0.840 0.851 0.929 0.013 0.106 
40 1.159 1.189 1.233 0.026 0.064 
41 0.900 0.905 0.944 0.006 0.049 
45 0.355 0.368 0.495 0.037 0.394 
Average 0.814 0.828 0.900 . . 
Group 4 
(MBMP) 
Day 1 Day 14 Day 30 D14 - D1 D30 - D1 
27 0.556 0.941 1.015 0.692 0.826 
29 0.477 0.345 0.393 -0.277 -0.176 
33 0.768 0.453 0.464 -0.410 -0.396 
36 0.978 0.544 0.517 -0.444 -0.471 
Average 0.695 0.571 0.597 . . 
Group 5 
(MAbBMP) 
Day 1 Day 14 Day 30 D14 - D1 D30 - D1 
18 0.998 1.049 1.153 0.051 0.155 
30 0.682 0.499 0.446 -0.268 -0.346 
34 1.147 1.203 1.208 0.049 0.053 
37 0.898 0.462 0.432 -0.486 -0.519 
Average 0.931 0.803 0.810 . . 
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Table A.9 Plasma Concentration of Tigecycline for all Goats in Groups 3 & 5, Days 0-30 
 
Group 3 (MAb) Group 5 (MAbBMP) 
 
Tigecycline concentration (ng/ml) Tigecycline concentration (ng/ml) 
Time 
(days) 
Goat 39 Goat 40 Goat 41 Goat 45 Goat 18 Goat 30 Goat 34 Goat 37 
0 0 0 0 0 0 0 0 0 
1 4.0 3.1 5.9 3.0 4.3 3.1 3.9 3.4 
2 3.2 . 3.1 2.8 3.3 2.8 3.2 3.1 
3 2.4 3.8 3.0 2.6 3.2 2.7 3.3 2.9 
4 . 3.5 2.7 2.6 3.4 2.6 3.2 3.2 
5 . 3.2 2.8 2.5 3.5 2.9 3.5 2.9 
6 2.5 3.4 2.7 2.9 . 2.7 3.7 3.6 
7 2.9 3.1 . 2.6 3.3 3.2 3.1 3.3 
9 3.1 3.9 . 2.5 3.1 2.5 3.4 3.3 
11 2.8 3.5 3.3 2.4 2.7 2.4 3.0 2.9 
13 3.3 2.8 3.4 2.7 2.5 2.5 2.9 3.1 
15 2.7 2.9 3.2 2.6 2.6 2.5 3.3 3.0 
17 2.6 3.2 3.8 2.6 0 2.4 2.5 3.6 
22 2.1 2.7 2.3 2.4 0 2.3 2.7 0 
26 0 2.1 0 2.2 0 2.4 2.6 0 
30 . 2.1 0 2.2 0 2.5 0 0 
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Table A.10 Plasma Concentration of Tobramycin for all Goats in Groups 3 & 5, Days 0-30 
 
Group 3 Group 5 
 
Tobramycin concentration (ng/ml) Tobramycin concentration (ng/ml) 
Time 
(days) 
Goat 39 Goat 40 Goat 41 Goat 45 Goat 18 Goat 30 Goat 34 Goat 37 
0 . . 0 0 0 0 0 0 
1 . 2.5 . 1.4 5.7 3.1 6.1 4.8 
2 2.5 2.3 1.6 1.4 3.6 3.0 4.6 3.7 
3 2.2 2.4 1.4 . 2.8 2.8 3.5 2.8 
4 2.2 . 1.6 . 2.9 2.5 . 2.6 
5 3.8 6.3 5.7 1.4 . 2.8 3.0 2.6 
6 3.3 4.5 4.1 8.2 . 2.4 2.6 2.1 
7 2.6 3.1 2.6 5.6 . 2.4 2.7 . 
9 . 2.8 . 3.0 2.6 2.4 2.8 2.5 
11 2.5 2.2 2.0 2.5 2.4 2.5 2.4 . 
13 . 2.4 1.8 2.2 2.5 2.7 3.0 . 
15 2.5 1.7 1.8 1.6 2.6 2.3 2.6 . 
17 2.2 1.7 1.5 1.7 2.5 2.7 2.6 2.6 
22 . 1.9 1.6 1.5 2.5 . . 2.5 
26 . . 1.3 . . . . 2.3 
30 . 1.9 1.4 1.5 2.7 . . . 
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Table A.11 Mean ± SEM Plasma Concentrations of Tigecycline & Tobramycin for all Goats in 
Groups 3 & 5, Days 0-30 
 
Tigecycline concentration 
(ng/ml) 
Tobramycin concentration (ng/ml) 
 
Groups 3 and 5 Group 3 Group 5 
Time (days) 
Least Square 
Mean 
Standard Error 
Least Square 
Mean 
Standard Error 
Least Square 
Mean 
Standard Error 
0 0.0 0.3 0.0 0.6 0.0 0.4 
1 3.8 0.3 2.0 0.6 4.9 0.4 
2 3.1 0.3 2.0 0.4 3.7 0.4 
3 3.0 0.3 2.0 0.5 3.0 0.4 
4 3.0 0.3 1.9 0.6 2.7 0.5 
5 3.0 0.3 4.3 0.4 2.8 0.5 
6 3.0 0.3 5.0 0.4 2.4 0.5 
7 3.1 0.3 3.5 0.4 2.5 0.6 
9 3.1 0.3 2.9 0.6 2.6 0.4 
11 2.9 0.3 2.3 0.4 2.4 0.5 
13 2.9 0. 2.2 0.5 2.7 0.5 
15 2.9 0.3 1.9 0.4 2.5 0.5 
17 2.6 0.3 1.7 0.4 2.6 0.4 
22 1.8 0.3 1.7 0.5 2.5 0.6 
26 1.1 0.3 1.3 0.9 2.3 0.9 
30 1.0 0.3 1.6 0.5 2.7 0.9 
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Table A.12 LS Means Differences Student’s t for Plasma Concentration of Tigecycline 
Level 
(day)      
Least Square 
Mean 
1 A 
    
3.833 
9 A B 
   
3.119 
2 
 
B 
   
3.082 
7 
 
B 
   
3.063 
5 
 
B 
   
3.036 
6 
 
B 
   
3.029 
4 
 
B 
   
3.010 
3 
 
B 
   
2.993 
13 
 
B 
   
2.908 
11 
 
B 
   
2.876 
15 
 
B 
   
2.851 
17 
 
B 
   
2.580 
22 
  
C 
  
1.809 
26 
  
C D 
 
1.143 
30 
   
D 
 
0.974 
0 
    
E 0.000 
Levels not connected by same letter are significantly different 
(α = 0.05). 
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Table A.13 LS Means Differences Student’s t for Plasma Concentration of Tobramycin 
Level 
(Tx,day)        
Least Square 
Mean 
3,6 A 
      
5.025 
5,1 A 
      
4.930 
3,5 A B 
     
4.290 
5,2 
 
B C 
    
3.710 
3,7 
 
B C D 
   
3.470 
5,3 
  
C D E 
  
2.955 
3,9 
 
B C D E F 
 
2.907 
5,5 
  
C D E F 
 
2.789 
5,13 
  
C D E F 
 
2.742 
5,4 
  
C D E F 
 
2.669 
5,30 
 
B C D E F 
 
2.663 
5,17 
  
C D E F 
 
2.600 
5,9 
  
C D E F 
 
2.583 
5,7 
  
C D E F 
 
2.516 
5,22 
  
C D E F 
 
2.489 
5,15 
  
C D E F 
 
2.472 
5,11 
  
C D E F 
 
2.445 
5,6 
   
D E F 
 
2.352 
3,11 
   
D E F 
 
2.305 
5,26 
  
C D E F 
 
2.295 
3,13 
    
E F 
 
2.165 
3,3 
    
E F 
 
1.984 
3,1 
    
E F 
 
1.967 
3,2 
    
E F 
 
1.940 
3,15 
    
E F 
 
1.918 
3,4 
    
E F 
 
1.888 
3,17 
     
F 
 
1.745 
3,22 
     
F 
 
1.658 
3,30 
     
F 
 
1.602 
3,26 
    
E F G 1.321 
5,0 
      
G 0.000 
3,0 
      
G 0.000 
Levels not connected by same letter are significantly different (α = 0.05). 
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Table A.14 Serum Concentration of rhBMP-2 for all Goats from all Groups, Days 0-30 
 
Serum concentration of rhBMP-2 (pg/ml) 
 
Group 1 (C) 
 
Group 2 (M) 
Time (days) Goat 32 Goat 35 Goat 38 Goat 43 
 
Goat 42 Goat 44 Goat 47 Goat 48 
0 87.0 73.7 73.7 78.7 
 
87.0 73.7 70.3 67.0 
1 72.0 57.0 73.7 73.7 
 
78.7 70.3 72.0 68.7 
2 83.7 68.7 20.3 18.7 
 
20.3 12.0 18.7 25.3 
3 35.3 18.7 17.0 . 
 
18.7 13.7 13.7 15.3 
4 27.0 13.7 96.0 89.3 
 
89.3 89.3 89.3 101.0 
5 104.3 96.0 87.7 96.0 
 
96.0 82.7 84.3 82.7 
6 99.3 86.0 103.7 88.7 
 
88.7 95.3 97.0 103.7 
7 100.3 97.0 147.0 100.3 
 
92.0 82.0 85.3 88.7 
9 47.8 32.8 34.0 40.3 
 
37.8 35.3 34.0 34.0 
11 44.0 29.0 34.0 36.5 
 
36.5 37.8 36.5 40.3 
13 39.0 32.8 31.5 32.8 
 
30.3 166.5 22.8 26.5 
15 39.0 24.0 29.0 30.3 
 
31.5 29.0 31.5 35.3 
17 52.3 39.8 39.8 39.8 
 
38.5 37.3 33.5 41.0 
22 104.8 48.5 44.8 44.8 
 
42.3 43.5 48.5 43.5 
25 48.7 30.3 38.7 37.0 
 
37.0 33.7 27.0 37.0 
30 55.3 33.7 38.7 48.7 
 
43.7 45.3 43.7 48.7 
 
Group 3 (MAb) 
 
Group 4 (MBMP) 
Time (days) Goat 39 Goat 40 Goat 41 Goat 45 
 
Goat 27 Goat 29 Goat 33 Goat 36 
0 77.0 82.0 78.7 73.7 
 
75.3 67.0 90.3 77.0 
1 72.0 75.3 75.3 68.7 
 
97.0 63.7 67.0 67.0 
2 25.3 13.7 25.3 20.3 
 
82.0 80.3 83.7 75.3 
3 10.3 15.3 18.7 18.7 
 
27.0 15.3 38.7 12.0 
4 99.3 89.3 112.7 107.7 
 
107.0 17.0 42.0 17.0 
5 86.0 89.3 96.0 92.7 
 
111.0 89.3 109.3 89.3 
6 100.3 90.3 102.0 93.7 
 
97.7 89.3 104.3 89.3 
7 85.3 87.0 88.7 93.7 
 
98.7 85.3 103.7 87.0 
9 35.3 35.3 40.3 36.5 
 
39.0 34.0 47.8 34.0 
11 36.5 39.0 37.8 41.5 
 
40.3 34.0 42.8 34.0 
13 24.0 27.8 39.0 31.5 
 
40.3 30.3 39.0 74.0 
15 31.5 35.3 34.0 32.8 
 
31.5 30.3 35.3 26.5 
17 39.8 36.0 39.8 42.3 
 
56.0 37.3 49.8 39.8 
22 46.0 167.3 184.8 46.0 
 
43.5 43.5 51.0 39.8 
25 38.7 37.0 40.3 43.7 
 
45.3 37.0 52.0 35.3 
30 32.0 50.3 45.3 52.0 
 
38.7 35.3 52.0 32.0 
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con’t Serum concentration of rhBMP-2 (pg/ml) 
 
Group 5 (MAbBMP) 
Time (days) Goat 18 goat 30 Goat 34 Goat 37 
0 78.7 88.7 75.3 77.0 
1 53.7 53.7 60.3 68.7 
2 72.0 67.0 72.0 83.7 
3 13.7 18.7 22.0 18.7 
4 12.0 17.0 17.0 25.3 
5 87.7 84.3 92.7 96.0 
6 94.3 94.3 87.7 99.3 
7 85.3 85.3 95.3 97.0 
9 36.5 32.8 35.3 36.5 
11 32.8 35.3 32.8 37.8 
13 54.0 27.8 29.0 36.5 
15 26.5 29.0 26.5 30.3 
17 39.8 43.5 44.8 46.0 
22 34.8 37.3 39.8 42.3 
25 32.0 40.3 45.3 53.7 
30 33.7 30.3 32.0 42.0 
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Table A.15 Mean ± SEM Serum Concentration of rhBMP-2 of all Goats from all Groups, Days 
0-30 
 
Serum concentration of rhBMP-2 (pg/ml) 
 
Group 1 (C) Group 2 (M) Group 3 (MAb) Group 4 (MBMP) Group 5 (MAbBMP) 
Time 
(days) 
Least 
Square 
Mean 
Standard 
Error 
Least 
Square 
Mean 
Standard 
Error 
Least 
Square 
Mean 
Standard 
Error 
Least 
Square 
Mean 
Standard 
Error 
Least 
Square 
Mean 
Standard 
Error 
0 78.3 7.9 74.5 7.9 77.8 7.9 77.4 7.9 79.9 7.9 
1 69.1 7.9 72.4 7.9 72.8 7.9 73.7 7.9 59.1 7.9 
2 47.8 7.9 19.1 7.9 21.2 7.9 80.3 7.9 73.7 7.9 
3 23.4 9.1 15.3 7.9 15.8 7.9 23.3 7.9 18.3 7.9 
4 56.5 7.9 92.3 7.9 102.3 7.9 45.8 7.9 17.8 7.9 
5 96.0 7.9 86.4 7.9 91.0 7.9 99.8 7.9 90.2 7.9 
6 94.4 7.9 96.2 7.9 96.6 7.9 95.2 7.9 93.9 7.9 
7 111.2 7.9 87.0 7.9 88.7 7.9 93.7 7.9 90.8 7.9 
9 38.7 7.9 35.3 7.9 36.8 7.9 38.7 7.9 35.3 7.9 
11 35.9 7.9 37.8 7.9 38.7 7.9 37.8 7.9 34.6 7.9 
13 34.0 7.9 61.5 7.9 30.6 7.9 45.9 7.9 36.8 7.9 
15 30.6 7.9 31.8 7.9 33.4 7.9 30.9 7.9 28.1 7.9 
17 42.9 7.9 37.6 7.9 39.4 7.9 45.7 7.9 43.5 7.9 
22 60.7 7.9 44.4 7.9 111.0 7.9 44.4 7.9 38.5 7.9 
25 38.7 7.9 33.7 7.9 39.9 7.9 42.4 7.9 42.8 7.9 
30 44.1 7.9 45.3 7.9 44.9 7.9 39.5 7.9 34.5 7.9 
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Table A.16 LS Means Differences Student’s t for Mean Serum Concentration of rhBMP-2 
Level 
(Tx, days)                       
Least 
Squares 
Mean 
1,7 A 
                     
111.167 
3,22 A 
                     
111.000 
3,4 A B 
                    
102.250 
4,5 A B C 
                   
99.750 
3,6 A B C D E 
                 
96.583 
2,6 A B C D 
                  
96.167 
1,5 A B C D E 
                 
96.000 
4,6 A B C D E F 
                
95.167 
1,6 A B C D E F G 
               
94.417 
5,6 A B C D E F G 
               
93.917 
4,7 A B C D E F G 
               
93.667 
2,4 A B C D E F G 
               
92.250 
3,5 A B C D E F G H 
              
91.000 
5,7 A B C D E F G H 
              
90.750 
5,5 A B C D E F G H 
              
90.167 
3,7 
 
B C D E F G H 
              
88.667 
2,7 
 
B C D E F G H 
              
87.000 
2,5 
 
B C D E F G H 
              
86.417 
4,2 
 
B C D E F G H I 
             
80.333 
5,0 
  
C D E F G H I 
             
79.917 
1,0 
  
C D E F G H I 
             
78.250 
3,0 
  
C D E F G H I J 
            
77.833 
4,0 
   
D E F G H I J 
            
77.417 
2,0 
    
E F G H I J 
            
74.500 
4,1 
      
G H I J 
            
73.667 
5,2 
     
F G H I J 
            
73.667 
3,1 
      
G H I J 
            
72.833 
2,1 
      
G H I J 
            
72.417 
1,1 
       
H I J K 
           
69.083 
2,13 
        
I J K L 
          
61.500 
1,22 
        
I J K L M 
         
60.688 
5,1 
        
I J K L M N 
        
59.083 
1,4 
         
J K L M N O 
       
56.500 
1,2 
          
K L M N O P 
      
47.833 
4,13 
           
L M N O P Q 
     
45.875 
4,4 
           
L M N O P Q 
     
45.750 
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4,17 
           
L M N O P Q 
     
45.688 
2,30 
           
L M N O P Q R 
    
45.333 
3,30 
           
L M N O P Q R 
    
44.917 
2,22 
           
L M N O P Q R 
    
44.438 
4,22 
           
L M N O P Q R 
    
44.438 
1,30 
           
L M N O P Q R 
    
44.083 
5,17 
           
L M N O P Q R 
    
43.500 
1,17 
           
L M N O P Q R S 
   
42.875 
5,25 
           
L M N O P Q R S 
   
42.833 
4,25 
           
L M N O P Q R S 
   
42.417 
3,25 
           
L M N O P Q R S T 
  
39.917 
4,30 
           
L M N O P Q R S T 
  
39.500 
3,17 
           
L M N O P Q R S T 
  
39.438 
4,9 
            
M N O P Q R S T 
  
38.688 
1,9 
             
N O P Q R S T 
  
38.688 
3,11 
            
M N O P Q R S T 
  
38.688 
1,25 
             
N O P Q R S T 
  
38.667 
5,22 
             
N O P Q R S T 
  
38.500 
2,11 
             
N O P Q R S T U 
 
37.750 
4,11 
             
N O P Q R S T U 
 
37.750 
2,17 
             
N O P Q R S T U 
 
37.563 
5,13 
              
O P Q R S T U V 36.813 
3,9 
              
O P Q R S T U V 36.813 
1,11 
              
O P Q R S T U V 35.875 
2,9 
              
O P Q R S T U V 35.250 
5,9 
              
O P Q R S T U V 35.250 
5,11 
              
O P Q R S T U V 34.625 
5,30 
              
O P Q R S T U V 34.500 
1,13 
               
P Q R S T U V 34.000 
2,25 
               
P Q R S T U V 33.667 
3,15 
               
P Q R S T U V 33.375 
2,15 
               
P Q R S T U V 31.813 
4,15 
               
P Q R S T U V 30.875 
1,15 
               
P Q R S T U V 30.563 
3,13 
               
P Q R S T U V 30.563 
5,15 
               
P Q R S T U V 28.063 
1,3 
                
Q R S T U V 23.390 
4,3 
                 
R S T U V 23.250 
3,2 
                  
S T U V 21.167 
2,2 
                   
T U V 19.083 
5,3 
                   
T U V 18.250 
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5,4 
                   
T U V 17.833 
3,3 
                    
U V 15.750 
2,3 
                     
V 15.333 
Levels not connected by same letter are significantly different (α = 0.05). 
 
Table A.17 Subjective Gross Evaluation of Periosteal & Endosteal Reactions on Histological 
Slides Using a Binomial Scoring System, Day 30 
Groups 
Goat (hind 
limb) 
Periosteal 
reaction 
Endosteal 
reaction 
1 (C) 
32 (right) 2 1 
35 (right) 2 1 
38 (left) 2 1 
43 (right) 2 1 
2 (M) 
42 (right) 2 2 
44 (left) 2 1 
47 (right) 2 2 
48 (left) 1 1 
3 (MAb) 
39 (left) 2 2 
40 (left) 1 2 
41 (left) 1 2 
45 (right) 1 2 
4 (MBMP) 
27 (left) 2 2 
29 (left) 2 2 
33 (right) 2 2 
36 (right) 2 1 
5 
(MAbBMP) 
18 (left) 2 2 
30 (left) 2 2 
34 (right) 2 2 
37 (left) 2 2 
Legend: score 1 = none or minimal reaction; score 2 = moderate 
to severe reaction. 
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Table A.18 Probability That a Goat From a Given Group had No or Minimal Endosteal Reaction 
Upon Gross Evaluation of the Histological Slides, Day 30 
Groups Probability 
1 (C) 1.00 
2 (M) 0.50 
3 (MAb) 0 
4 (MBMP) 0.25 
5 (MAbBMP) 0 
 
Table A.19 Qualitative Gross Evaluation of Surface of Periosteal & Endosteal Reactions and 
Surface of Endosteal Reaction:Surface of Medullary Cavity Ratio on Histological Slides Using a 
Digital Caliper, Day 30 
  
Periosteal reaction Endosteal reaction Medullary cavity Proportion 
Gr 
Goat 
(hindlimb) 
Width 
(mm) 
Length 
(mm) 
Area 
(mm
2
) 
Width 
(mm) 
Length 
(mm) 
Area 
(mm
2
) 
Width 
(mm) 
Length 
(mm) 
Area 
(mm
2
) 
Endos. Rx 
/ medul. 
cavit. 
1
 (
C
) 
32 (right) 2.81 11.86 33.33 0.48 1.09 0.52 12.71 13.31 169.17 0.0031 
35 (right) 1.37 21.69 29.72 0.7 0.74 0.52 14.21 12.64 179.61 0.0029 
38 (left) 1.2 22.54 27.05 1.44 0.65 0.94 14.74 12.55 184.99 0.0051 
43 (right) 1.76 14.67 25.82 0.47 3.41 1.60 9.46 9.44 89.30 0.0179 
2
 (
M
) 
42 (right) 1.98 11.28 22.33 7.06 8.18 57.75 9.68 8.18 79.18 0.7293 
44 (left) 1.44 16.76 24.13 6.4 8.07 51.65 11.77 13.54 159.37 0.3241 
47 (right) 2.54 15.58 39.57 6.26 8.16 51.08 10.67 9.59 102.33 0.4992 
48 (left) 0.86 23.91 20.56 4.8 9.94 47.71 17.61 16.66 293.38 0.1626 
3
 (
M
A
b
) 
39 (left) 2.53 17.49 44.25 6.84 10.56 72.23 11.97 11.27 134.90 0.5354 
40 (left) 0.98 14.34 14.05 5.29 8.72 46.13 8.83 8.72 77.00 0.5991 
41 (left) 0.39 12.87 5.02 6.84 7.6 51.98 10.25 9.57 98.09 0.5299 
45 (right) 0.28 15.61 4.37 6.85 10.5 71.93 11.73 12.12 142.17 0.5059 
4
 (
M
B
M
P
) 27 (left) 4.57 19.77 90.35 9.75 9.11 88.82 10.1 10.09 101.91 0.8716 
29 (left) 1.73 15.11 26.14 9.07 13.08 118.64 13.07 13.08 170.96 0.6940 
33 (right) 4.28 21.47 91.89 8.94 11.68 104.42 12.82 12.5 160.25 0.6516 
36 (right) 4.04 18.48 74.66 8.1 8.56 69.34 14.33 13.28 190.30 0.3643 
5
 (
M
A
b
B
M
P
) 18 (left) 4.77 17.6 83.95 5.38 8.67 46.64 10.24 9.84 100.76 0.4629 
30 (left) 1.58 12.18 19.24 5.2 9.6 49.92 11.18 11.99 134.05 0.3724 
34 (right) 2.18 6.76 14.74 6.36 8.7 55.33 12.53 12.57 157.50 0.3513 
37 (left) 2.59 18.74 48.54 6.62 6.74 44.62 10.69 10.4 111.18 0.4013 
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Table A.20 Mean ± SEM Surface of Periosteal & Endosteal Reactions and Mean ± SEM Surface 
of Endosteal Reaction:Surface of Medullary Cavity Ratio as Qualitatively Evaluated Using a 
Digital Caliper, Day 30 
 
Periosteal rx area 
(mm
2
) 
Endosteal reaction 
area (mm
2
) 
Proport. endosteal rx / 
medull. cav. 
Group 
Least 
Square 
Mean 
Standard 
Error 
Least 
Square 
Mean 
Standard 
Error 
Least 
Square 
Mean 
Standard 
Error 
1 (C) 28.98 10.97 0.89 5.79 0.0072 0.0732 
2 (M) 26.65 10.97 52.05 5.79 0.4288 0.0732 
3 (MAb) 16.92 10.97 60.57 5.79 0.5426 0.0732 
4 (MBMP) 70.76 10.97 95.30 5.79 0.6454 0.0732 
5 
(MAbBMP) 
41.62 10.97 49.13 5.79 0.3970 0.0732 
 
Table A.21 LS Means Differences Student’s t for Mean Surface of Periosteal Reaction 
Determined by Qualitative Gross Evaluation (Digital Caliper) of the Histological Slides 
Surface of periosteal reaction (mm
2
) 
Level 
(group)   
Least Squares 
Mean 
4 A 
 
70.76 
5 A B 41.62 
1 
 
B 28.98 
2 
 
B 26.65 
3 
 
B 16.92 
Levels not connected by same letter are 
significantly different (α = 0.05). 
 
Table A.22 LS Means Differences Student’s t for Mean Surface of Endosteal Reaction 
Determined by Qualitative Gross Evaluation (Digital Caliper) of the Histological Slides 
Surface of endosteal reaction (mm
2
) 
Level 
(group)    
Least Squares 
Mean 
4 A 
  
95.30 
3 
 
B 
 
60.57 
2 
 
B 
 
52.05 
5 
 
B 
 
49.13 
1 
  
C 0.89 
Levels not connected by same letter are significantly 
different (α = 0.05). 
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Table A.23 Percent Filling of Bone Defect Evaluated Using Red Channels Images for all Goats 
from all Groups, Day 30  
Group 
Goat 
(hind limb) 
Rolling ball radius 
(pixels) 
Resolution 
(pixels/um) 
Area of 
interest 
(µm
2
) 
% bone 
filling 
1 (C) 
32 (right) 50 0.180 4509787.74 36.46 
35 (right) 50 0.200 2037196.63 32.47 
38 (left) 50 0.200 1931065.21 32.02 
43 (right) 50 0.204 4675358.09 43.03 
2 (M) 
42 (right) 50 0.215 7101342.75 58.07 
44 (left) 50 0.180 4149434.45 42.81 
47 (right) 50 0.201 5387399.06 45.15 
48 (left) 50 0.206 2182960.90 39.74 
3 (MAb) 
39 (left) 50 0.194 2337628.31 29.32 
40 (left) 50 0.193 5274062.89 43.30 
41 (left) 50 0.158 4139646.13 31.59 
45 (right) 50 0.210 3155045.84 33.36 
4 (MBMP) 
27 (left) 50 0.167 3047995.78 23.69 
29 (left) 50 0.178 3456462.72 49.54 
33 (right) 50 0.138 2566649.71 26.55 
36 (right) 50 0.203 3090864.21 31.74 
5 
(MAbBMP) 
18 (left) 50 0.150 5542739.82 36.30 
30 (left) 200 0.200 6434956.31 50.59 
34 (right) 100 0.218 1951966.00 17.24 
37 (left) 50 0.154 3872465.66 32.56 
Threshold was set at 149 for all red channels image analysis. 
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Table A.24 Percent Filling of Bone Defect Evaluated Using Green Channels Images for all Goats 
from all Groups, Day 30 
Group 
Goat 
(hind limb) 
Area (µm
2
) 
% bone 
filling 
1 (C) 
32 (right) 4494916.93 36.34 
35 (right) 1731579.60 27.60 
38 (left) 1864363.94 30.92 
43 (right) 4496312.61 41.38 
2 (M) 
42 (right) 6953885.49 56.86 
44 (left) 4124225.06 42.55 
47 (right) 5434039.67 45.54 
48 (left) 2121027.09 38.61 
3 (MAb) 
39 (left) 2349240.23 29.47 
40 (left) 4222214.70 34.66 
41 (left) 4165566.45 31.79 
45 (right) 3104144.51 32.82 
4 (MBMP) 
27 (left) 2585431.09 20.09 
29 (left) 3051746.09 43.74 
33 (right) 2478200.99 25.64 
36 (right) 2956164.03 30.35 
5 
(MAbBMP) 
18 (left) 5957149.04 39.01 
30 (left) 6284750.85 49.41 
34 (right) 1871911.80 16.53 
37 (left) 3228000.20 27.14 
Threshold was set at 149 for all green channels image 
analysis. Rolling ball radius and resolution were the same 
for the green channels images as the red channels images. 
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Table A.25 Percent Filling of Bone Defect Evaluated Using Blue Channels Images for all Goats 
from all Groups, Day 30 
Group 
Goat 
(hind limb) 
Area (µm
2
) % Filling 
Standard 
Error 
1 (C) 
32 (right) 3590470.67 29.03 4.57 
35 (right) 970227.10 15.46 4.57 
38 (left) 1746619.11 28.96 4.57 
43 (right) 3277386.55 30.16 4.57 
2 (M) 
42 (right) 6810298.45 55.69 4.57 
44 (left) 4014779.43 41.42 4.57 
47 (right) 5549686.55 46.51 4.57 
48 (left) 1847138.87 33.63 4.57 
3 (MAb) 
39 (left) 2571139.28 32.25 4.57 
40 (left) 3586397.01 29.44 4.57 
41 (left) 4625721.79 35.30 4.57 
45 (right) 3136571.21 33.16 4.57 
4 (MBMP) 
27 (left) 1587334.77 12.34 4.57 
29 (left) 1021944.38 14.65 4.57 
33 (right) 2380722.59 24.63 4.57 
36 (right) 2274261.03 23.35 4.57 
5 
(MAbBMP) 
18 (left) 6409484.98 41.98 4.57 
30 (left) 6424950.93 50.51 4.57 
34 (right) 2426496.24 21.43 4.57 
37 (left) 2256920.34 18.98 4.57 
Threshold was 200 for all blue channels image analysis. Rolling ball 
radius and resolution were the same for the blue channels images as 
the red channels images. 
68 
 
 
Table A.26 Mean ± SEM Percent Filling of Bone Defect Evaluated by Computerized Image 
Analysis for all Goats from all Groups, Day 30 
 
Red channels images  Green channels images Blue channels images 
Group LS Mean 
Standard 
Error 
LS Mean 
Standard 
Error 
LS Mean 
Standard 
Error 
1 (C) 35.99 4.75 34.06 4.52 25.90 4.57 
2 (M) 46.44 4.75 45.89 4.52 44.31 4.57 
3 (MAb) 34.39 4.75 32.19 4.52 32.54 4.57 
4 (MBMP) 32.88 4.75 29.96 4.52 18.74 4.57 
5 (MAbBMP) 34.17 4.75 33.02 4.52 33.22 4.57 
 
Table A.27 LS Means Differences Student’s t for Percent Filling of Bone Defect Evaluated by 
Computerized Image Analysis (Blue Channels Images) for all Goats from all Groups, Day 30 
Blue channels 
Level 
(treatment)    
Least Squares 
Mean 
2 A 
  
44.31 
5 A B 
 
33.22 
3 A B 
 
32.54 
1 
 
B C 25.90 
4 
  
C 18.74 
Levels not connected by same letter are significantly 
different (α = 0.05). 
 
Table A.28 Characteristics of the in vitro elution of tobramycin from different non 
biodegradable and biodegradable local delivery systems for bone 
Local delivery 
system 
Duration of 
release 
Mean peak 
release 
Time when 
peak observed 
References 
PMMA beads 84 days 34.3 µg/ml Day 1 142 
PMMA beads 30 days 234-299 mg/l Day 1 
146
 
PMMA beads 220 days > 250 mg/l Day 1 
147
 PLA beads 42 days N/A Day 1 
PLGA beads 36-65 days* N/A Day 1 & day 25 
PLGA-PEG 
copolymer 
27 days N/A Day 1 
49
 
Bone graft 7 days 
17047 µg/g 
pellet 
Day 1 
50
 
Demineralized 
bone matrix 
4 days 
11 437 µg/g 
pellet 
Day 1 
Plaster of Paris 4 days 
4294 µg/g 
pellet 
Day 1 
Legend: PLGA = poly(DL-lactic-co-glycolic acid); PEG = poly(ethylene glycol); PLA = polylactic 
acid;* depending on the ratio of DL-lactide and coglycolide; N/A: unavailable information. 
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Appendix B - Supplementary Figures 
 
Figure B.1 Photograph of the Novel Polymeric Bone Matrix 
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Figure B.2 Equation to compute the volume of a cylinder 
 
 
 
 
 
 
 
 
Figure B.3 Equation used to compute the percent change in BMD on day 14 and 30 
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Figure B.4 In Vitro Elution Curve of Tigecycline from the Novel Polymeric Bone Matrix 
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Figure B.5 In Vitro Elution Curve of Tigecycline from the Matrix Using a log10 Vertical Axis 
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Figure B.6 In Vitro Elution Curve of Tobramycin From the Matrix 
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Figure B.7 In Vitro Elution Curve of Tobramycin from the Matrix Using a log10 Vertical Axis 
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Figure B.8 In Vitro Elution Curve of rhBMP-2 From the Matrix 
 
 
 
 
Figure B.9 Integrity of the 
Antimicrobial Impregnated 
Matrix at the End of the In 
Vitro Experiment, Day 30 
 
Figure B.10 Integrity of the 
rhBMP-2 Impregnated Matrix 
at the End of the In Vitro 
Experiment, Day 30 
 
Figure B.11 Integrity of the 
Co-impregnated Matrix at the 
End of the In Vitro 
Experiment, Day 30 
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Figure B.12 Mean ± SEM Plasma Concentration of Tigecycline in Groups 3 & 5, Days 0-30 
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Figure B.13 Mean ± SEM Plasma Concentration of Tobramycin in Groups 3 & 5, Days 0-30 
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Figure B.14 Mean ± SEM Serum Concentration of rhBMP-2 for all Groups, Days 0-30 
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Figure B.15 Effect of Treatment on Mean Surface of Periosteal and Endosteal Reaction for all 
Groups, Day 30 
Bars that share a letter (a-c) are not statistically different at P < 0.05. 
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Figure B.16 Effect of Treatment on Surface of Endosteal Reaction:Medullary Cavity Ratio for 
all Groups, Day 30 
Bars that share a letter (a-b) are not statistically different at P < 0.05. 
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Figure B.17 Mean Percent Filling of Bone Defects Evaluated by Computerized Image Analysis 
of the Three Fragmented Images (Red, Green, and Blue Channels) for all Groups, Day 30 
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Figure B.18 Mean Percent Filling of Bone Defects Evaluated by Computerized Image Analysis 
of the Blue Channels Images, Day 30 
Bars that share a letter (a-b) are not statistically different at P < 0.05. 
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Table B.1 Photographs of Undecalcified Bone Defects; Toluidine Blue Stained Histological 
Slides under 2X Objective for All Goats; Day 30 
Gr 1 (C) 
 
32 (right) 
 
35 (right) 
 
38 (left) 
 
43 (right) 
Gr 2 (M) 
 
42 (right) 
 
44 (left) 
 
47 (right) 
 
48 (left) 
Gr 3 (MAb) 
 
39 (left) 
 
40 (left) 
 
41 (left) 
 
45 (right) 
Gr 4 (MBMP) 
 
27 (left) 
 
29 (left) 
 
33 (right) 
 
36 (right) 
Gr 5 (MAbBMP) 
 
18 (left) 
 
30 (left) 
 
34 (right) 
 
37 (left) 
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Appendix C - Protocol for Image Analysis Using ImageJ Software 
Software: ImageJ 1.42q, Wayne Rasband, National Institutes of Health, USA, 
http://rsb.info.nih.gov/ij. 
Steps: 
1. File  open, choose image, click OK. 
2. Image  Rotate  Arbitrarily… In the new window, choose the angle of rotation in 
degrees, check the preview box, then click OK. 
 
Figure C.1 Image Analysis, Step 2. 
  
3. Using the rectangle selection tool, make a selection of the area to crop. Then, Image 
 Crop 
 
Figure C.2 Image Analysis, Step 3. 
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4. Process  Substract Background, √check the preview box, then click OK. 
 
Figure C.3 Image Analysis, Step 4. 
The Rolling Ball Radius was kept at 50.0 pixels for each images and the Light Background box 
was always checked. 
 
5. Image  Adjust  Brightness & Contrast. 
 
Figure C.4 Image Analysis, Step 5. 
 
6. Click Auto, then click Apply. Close the window. 
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Figure C.5 Image Analysis, Step 6. 
 
7. File  Save As  Tiff… The image was then saved under DSCNxxxx-tagx-1 in file “1. 
after substract background”. 
 
 Figure C.6 Image Analysis, Step 7. 
 
8. The width of the bone defect was measured using the line selection tool. 
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 Figure C.7 Image Analysis, Step 8. 
Measurement of the bone defect width. 
 
9. Analyse  Set Scale. 
 
Figure C.8 Image Analysis, Step 9. 
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10. The length of the line is automatically entered as “Distance in Pixels”. Enter the 
“Known Distance” as 3500 µm (the width of the bone defect). Enter the “Units of Length” as 
um. Then, click OK. 
 
Figure C.9 Image Analysis, Step 10. 
The scale was then noted into the data table. (On this example, the scale was 0.180 pixels/μm). 
 
11. Image  Save As  .Tiff The image was then saved under DSCNxxxx-tagx-2 in file 
“2. after setting scale”. 
12. Analyse  Tools  Scale Bar…  
 
Figure C.10 Image Analysis, Step 12. 
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13. Replace the parameters as needed. Then, click OK. 
 
Figure C.11 Image Analysis, Step 13. 
For all pictures, the parameters were: Width in µm = 950; Height in pixels = 4; Font size = 22; 
Color = Black; Background = White; Location = Lower Left; Bold Text 
 
14. Image  Save As  .Tiff  The image was then saved under DSCNxxxx-tagx-3 in file 
“3. with scale on image”. 
15. Select the area of interest (cortical bone defect) using the freehand shape selection 
tool. 
 
85 
 
Figure C.12 Image Analysis, Step 15. 
 
16. Image  Type  RGB Stack (to split the image into red, green and blue channels) 
 
Figure C.13 Image Analysis, Step 16. 
 
 
Figure C.14 Image Splitted into Red Channels. 
An area of interest is highlighted using the selection tool. 
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17. Image  Save As  .Tiff  The image was then saved under DSCNxxxx-tagx-4 in file 
“4. stacks RGB images”. 
18. Image  Adjust  Threshold 
 
Figure C.15 Image Analysis, Step 18. 
The threshold was always adjusted to 149 for each red channel images. 
 
19. Analyse  Set Measurements. √ Check “Area”, “Area Fraction”, “Limit to Threshold” 
and “Display Label”. Then, click OK. 
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Figure C.16 Image Analysis, Step 19. 
 
20. Press “m” ( or Analyse  Measure) to display area and % area in the Results 
window. 
21. Select the green channel by moving the lower bar on the picture and repeat steps 18 
to 20. The threshold was always adjusted to 149 for each green channel images. 
22. Select the blue channel by moving the lower bar on the picture and repeat steps 18 
to 20. The threshold was always adjusted to 200 for each blue channel images. 
23. Right click in the result window and “Save As” .doc or “Copy” to another text file. 
 
